The Life Sciences Report

Rocket Doctor AI Delivers 3625 U.S. Patient Visits in July and August

Thu, 17 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/17/2026

Rocket Doctor AI reports 3,625 completed U.S. patient visits in the first two months of Q3 2026. The update highlights ongoing U.S. expansion and telehealth momentum for retail investors.

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) posted 3,625 completed U.S. patient visits during July and August 2026, in a recent press release. That total reached 93 percent of the 3,911 visits recorded across the entire second quarter.

The strong two-month run comes as Medicare telehealth rules remain extended through the end of 2027. Retail investors are watching how the company converts rising visit volume into recognized revenue while it scales its platform.

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) distinguishes between in-network and out-of-network patients. In-network visits require both the patient and physician to be enrolled with the payer for claims to qualify for payment. Out-of-network visits are accepted to grow adoption, and any amounts recovered from out-of-network claims are recognized as revenue only when cash is received.

Why the Visit Growth Matters Now

U.S. operational metrics for the first two months of the third quarter of 2026, with completed patient visits reaching 3,625 for the two-month period ended Aug. 31 show the company is maintaining momentum after its second-quarter results.

Clinical hours reached 1,555 in the same period, or 78 percent of the prior quarter total. Certain revenues are recorded on a cash basis, so a timing lag exists between visits and revenue recognition.

Company Advantage in Virtual Care Delivery

The platform was built by physicians for physicians. This design supports independent practice management and helps address access gaps, especially in rural areas.

The company is also moving into value-based primary care agreements that assign patient panels and generate recurring per-member-per-month payments instead of one-off visit fees.

Key Assets and Next Catalysts

Rocket Doctor AI's September 2026 investor overview identified Florida and Texas as part of its state expansion pipeline, covering roughly 17.8 million Medicare and Medicaid lives. In California, New York, and Maryland, the company has 81 signed physicians, with 31 already active and 50 in credentialing.

Physician capacity stands at three times the current active levels. The first value-based agreement covers an initial panel of 30,000 members and spans Commercial HMO, PPO, Medicare Advantage, D-SNP, and Medi-Cal plans.

Broader Telehealth Sector Timing

According to a February 26 update from the Centers for Medicare & Medicaid Services, Medicare beneficiaries can receive telehealth services anywhere in the United States and territories through December 31, 2027. Rural Health Clinics and Federally Qualified Health Centers can continue billing for non-behavioral health services delivered remotely, and audio-only options remain available.

An August 4 report from Johns Hopkins Medicine noted that the health system has conducted nearly 3 million remote visits since March 2020. The report highlighted telemedicine's use in primary care, specialty consultations, and chronic condition management.

Analyst Views and Valuation Context¹

Technical analyst Stewart Thomson wrote on March 17 that the platform expands healthcare access and rated the stock a Strong Speculative Buy with price targets of CA$0.80 short-term, CA$1.00 medium-term, and CA$1.60 long-term.

On June 11, Fundamental Research Corp. analyst Sid Rajeev reiterated a Buy rating and CA$1.55 target, citing U.S. expansion and rising patient volumes as drivers for future improvement. [OWNERSHIP_CHART-10594]

Share Structure and Near-Term Events²

Rocket Doctor AI Inc. has a market capitalization of approximately CA$59.61 million and 101.55 million shares outstanding. The 52-week range is CA$0.50 to CA$0.98.

Management and insiders own 4.24 percent of the shares.

Key Investor Takeaways

3,625 U.S. visits in two months equal 93 percent of the prior full quarter, showing sustained operational momentum.
Medicare telehealth flexibilities extended through 2027 provide a supportive regulatory backdrop for continued growth.
Value-based agreements shift revenue toward recurring per-member-per-month payments and assign dedicated patient panels.
Expansion pipeline targets 17.8 million covered lives in Florida and Texas, while physician capacity remains three times current active levels.
Two analysts have issued or reiterated Buy or Strong Speculative Buy ratings, with price targets ranging from CA$0.80 to CA$1.60.¹
Out-of-network visits build volume and support future payer contracting, even though revenue is recognized only on cash receipt.

Common Questions from Investors

What drove the 3,625 visits in July and August?

The company reported continued U.S. platform adoption and physician activity that produced 93 percent of the prior quarter's total in just two months.

How does the company recognize revenue from out-of-network visits?

Out-of-network revenue is recorded only when cash is actually received because collection is uncertain. In-network claims follow standard payer enrollment rules.

What is the size of the value-based care agreement?

The initial California agreement covers 30,000 covered members under a recurring per-member-per-month model that includes multiple Medicare and commercial lines.

Which states are next for expansion?

Florida and Texas represent the near-term pipeline with roughly 17.8 million Medicare and Medicaid covered lives targeted through existing payer relationships.

Rocket Doctor AI continues to balance early-stage U.S. adoption strategies with longer-term payer contracting and value-based care models. Investors should monitor quarterly visit trends, network conversion rates, and progress on the Florida and Texas pipeline for further clarity on revenue timing.

Important Disclosures:

Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.

2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: AIDR:CSE; AIRDF:OTC; 939:FRA, )

US Patient Visits Reach 93% of Prior Quarter's Total in Two Months

Thu, 17 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/17/2026

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported 3,625 completed U.S. patient visits in July and August, alongside 1,555 clinical hours as its U.S. operations expanded.

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported U.S. operational metrics for the first two months of the third quarter of 2026, with completed patient visits reaching 3,625 for the two-month period ended Aug. 31. That represented 93% of the 3,911 completed visits recorded during the entire three-month second quarter of 2026.

U.S. clinical hours reached 1,555 during July and August, representing 78% of the 1,987.5 clinical hours recorded for the entire second quarter. The update followed the company's second-quarter 2026 financial and operational results announced Sept. 1.

The company noted that certain U.S. revenues are recognized on a cash basis, creating a timing lag between patient visits and corresponding revenue recognition.

For its U.S. operations, Rocket Doctor AI distinguishes between in-network and out-of-network patients when determining reimbursement eligibility for visits conducted through its platform. For in-network patients, both the patient and treating physician must be enrolled with the applicable insurance provider, Medicare, or Medicaid, for a reimbursement claim to be eligible for payment.

The company permits out-of-network patients to access its platform as part of its strategy to drive adoption and expand its user base during the early stage of its U.S. market development. While reimbursement for out-of-network visits is generally not expected, the company submits claims for those visits where possible because certain claims may be approved at the payer's discretion.

Amounts recovered from out-of-network claims are recognized as revenue only upon actual cash receipt due to the uncertainty of collection associated with those visits. Management said it would continue evaluating network coverage and payer relationships with a view to converting out-of-network patients and physicians to in-network status over time.

Virtual Care Moves Deeper Into U.S. Healthcare

According to a February 26 update from the Centers for Medicare & Medicaid Services, Medicare beneficiaries could receive telehealth services anywhere in the United States and its territories through December 31, 2027. CMS stated, "Through December 31, 2027, beneficiaries can receive Medicare telehealth services anywhere in the United States and territories." An extended range of practitioners could also bill for Medicare telehealth services through that date.

CMS reported that Rural Health Clinics and Federally Qualified Health Centers could continue billing for non-behavioral health services delivered through telecommunications technology through the end of 2027, while patients could receive those services from their homes or other geographic locations. Audio-only telehealth also remained available in patients' homes through December 31, 2027.

Technical analyst Stewart Thomson rated Rocket Doctor AI a "Strong Speculative Buy."¹

An August 4 report from Johns Hopkins Medicine described telemedicine as a standing part of healthcare delivery, with practitioners conducting tens of thousands of virtual visits each month across primary care and nearly every specialty. Helen K. Hughes, M.D., M.P.H., medical director for the Johns Hopkins Office of Telemedicine, said, "Since March 2020, we have delivered almost 3 million remote visits to patients."

Johns Hopkins reported that telemedicine reduced the need for travel and could support specialty consultations, primary care, and chronic-condition management. Virtual visits were used for reviewing laboratory results, adjusting medications, checking blood pressure or blood sugar, and following up after hospital stays. Connected devices could also send blood pressure, weight, glucose, and heart-rhythm readings to care teams between visits.

Analysts Point to U.S. Expansion and Patient Growth

¹Technical analyst Stewart Thomson wrote on March 17 that Rocket Doctor AI's physician-developed digital health platform was designed around clinicians' needs and could expand access to healthcare, including in rural communities.

"Virtual care offers convenience, flexibility, and ongoing access to a healthcare team, making it an excellent alternative to traditional clinic visits," Thomson wrote. "However, not all 'virtual care' platforms and services are alike."

Thomson rated Rocket Doctor AI a "Strong Speculative Buy," with a short-term technical price target of CA$0.80, a medium-term target of CA$1.00, and a long-term target of CA$1.60.

On June 11, Fundamental Research Corp. analyst Sid Rajeev reiterated his "Buy" rating and CA$1.55 price target. Rajeev acknowledged higher costs and lower-than-expected patient volumes in the first quarter while citing U.S. expansion, patient volumes, and liquidity in his outlook.

"Supported by U.S. expansion, rising patient volumes, and sufficient liquidity, we expect meaningful operational and financial improvement over the coming quarters," Rajeev wrote.

U.S. Expansion, Physician Capacity, and Value-Based Care

Rocket Doctor AI's September 2026 investor overview identified Florida and Texas as part of its state expansion pipeline, representing approximately 17.8 million covered lives through Medicare and Medicaid. The presentation listed approximately 9 million covered lives in Florida and approximately 8.8 million in Texas and identified the strategy as extending existing relationships with payers.

The presentation reported 81 physicians signed in California, New York, and Maryland. Of those, 31 were clinically active, and 50 were credentialing. It also listed physician capacity pending at three times the current level.

Rocket Doctor AI also described its first value-based primary care agreement with a California independent physician association. The initial panel included 30,000 covered members, while the presentation reported more than 5 million patients that the company could reach in-network and listed nine of 65 payers and health plans.

Under the agreement, physicians are assigned patient panels rather than only receiving one-off visits. They are paid under a recurring per-member-per-month care model rather than solely on a one-off visit basis. The agreement covers Commercial HMO and PPO, Medicare Advantage, D-SNP, and Medi-Cal. [OWNERSHIP_CHART-10594]

The presentation stated that the structure provides recurring revenue beginning before a patient books and continuity of care. It also described California as the company's lowest-cost and highest-volume state. Rocket Doctor AI said it could pursue the same structure with other plans as it grows, with patients arriving through the plan rather than through an ad auction.

The company's U.S. payer approach included four channels: Medicaid and Medicaid Managed Care, Medicare and Medicare Advantage, HR and employer benefits and commercial insurance, and out-of-network patients. The presentation stated that each payer could provide access to 1 million to 2 million or more covered lives and create repeatable patient volume.

Rocket Doctor AI also identified its out-of-network activity as part of its payer strategy. The presentation stated that out-of-network visits build patient volume, demonstrate demand to payers, strengthen future contracting, and can convert to revenue. It described the stated strategic purpose as using patient demand in payer conversations.

Ownership & Share Information²

Rocket Doctor AI Inc. has a market cap of approximately CA$59.61 million, with 101.55 million shares outstanding. The company's 52-week range is CA$0.50-CA$0.98.

Management & Insiders own 4.24% of shares.

FAQs

What is Rocket Doctor AI?

Rocket Doctor AI Inc. is a digital health technology company redefining modern healthcare by strategically utilizing physician-built AI and best clinical practices to address systemic challenges and inefficiencies within the sector. RDAI delivers AI-powered solutions across the entire continuum of care, committed to making high-quality healthcare more scalable, equitable, and patient-centered.

The cornerstones of its portfolio are a digital health platform and marketplace empowering physicians to independently build and manage their own virtual or hybrid practices and its proprietary Global Library of Medicine (GLM), a comprehensive, personalized AI engine and clinically validated decision support system developed with input from hundreds of physicians worldwide.

The company is operating in Canada and the United States, with a focus on its United States growth.

How many U.S. patient visits has Rocket Doctor AI reported to date in Q3 2026?

Rocket Doctor AI reported 3,625 completed U.S. patient visits during July and August 2026. That represented 93% of the 3,911 completed U.S. patient visits recorded during the entire second quarter.

Are Rocket Doctor AI's U.S. patient visits increasing?

Rocket Doctor AI completed 3,625 U.S. patient visits during the first two months of the third quarter, compared with 3,911 during the entire three-month second quarter.

How many U.S. clinical hours did Rocket Doctor AI report?

Rocket Doctor AI recorded 1,555 U.S. clinical hours during July and August 2026, equal to 78% of the 1,987.5 clinical hours recorded during the entire second quarter.

How does Rocket Doctor AI make money from U.S. telehealth visits?

Rocket Doctor AI distinguishes between in-network and out-of-network patients for reimbursement eligibility. For an in-network claim to be eligible for payment, both the patient and treating physician must be enrolled with the applicable insurance provider, Medicare, or Medicaid. Certain U.S. revenues are recognized on a cash basis.

Why does Rocket Doctor AI accept out-of-network telehealth patients?

The company permits out-of-network patients to use its platform to drive adoption and expand its user base. It submits claims for those visits where possible, although reimbursement generally is not expected, and any recovered amounts are recognized as revenue upon cash receipt.

How large is Rocket Doctor AI's U.S. healthcare network?

Rocket Doctor AI's September investor presentation reported approximately 24 million in-network covered lives through payer partners across California, New York, and Maryland. The presentation also identified Florida and Texas as an expansion pipeline representing approximately 17.8 million Medicare and Medicaid covered lives.

What is Rocket Doctor AI doing in value-based healthcare?

Rocket Doctor AI reported its first value-based primary care agreement with a California independent physician association. The initial panel included 30,000 covered members, with physicians assigned patient panels and paid under a recurring per-member-per-month care model.

What are analysts saying about Rocket Doctor AI stock?

¹Technical analyst Stewart Thomson rated Rocket Doctor AI a "Strong Speculative Buy" on March 17, with technical price targets of CA$0.80, CA$1.00, and CA$1.60 across short-, medium-, and long-term periods.

Fundamental Research Corp. analyst Sid Rajeev reiterated a "Buy" rating and CA$1.55 price target on June 11.

Important Disclosures:

Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: AIDR:CSE; AIRDF:OTC; 939:FRA, )

BioLargo Subsidiary Secures Spartan Medical Deal for ViaCLYR Government Sales

Thu, 10 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/10/2026

BioLargo subsidiary Clyra enters an exclusive reseller agreement with Spartan Medical for ViaCLYR wound care solution targeting U.S. government facilities and ECAT listing amid expanding wound care demand.

BioLargo Inc. (BLGO:OTCQX) has secured a key commercial channel through its Clyra Medical Technologies subsidiary, according to a September 3 release .

The exclusive agreement with Spartan Medical Inc. opens direct access to U.S. government healthcare facilities worldwide for the FDA-cleared ViaCLYR advanced wound irrigation solution.

This development creates a dedicated pathway for federal purchasing and distribution, strengthening Clyra's position as it scales manufacturing.

Why the Spartan Medical Agreement Matters Now

The deal represents Clyra's third reseller arrangement and specifically targets government buyers, including VA/DoD facilities. ViaCLYR has been added to the Defense Logistics Agency Electronic Catalog, making it available for resale across multiple federal agencies and certain VA-funded civilian hospitals. Spartan Medical, a veteran-owned contractor, will offer the product at parity pricing.

BioLargo CEO Dennis Calvert highlighted how this channel complements existing U.S. and international distribution partners while supporting revenue growth ahead of the planned national launch of the surgical product Bioclynse next year.

Company Advantage Through Clyrasept Technology

ViaCLYR is powered by Clyrasept Copper-Iodine Complex Solution. Clinical testing showed it kills 99.9999% of 18 pathogens within one minute and maintains 72-hour antimicrobial activity without reapplication. The solution is non-cytotoxic and does not require rinsing. The FDA 510(k) clearance covers cleansing, irrigating, and debriding wounds rather than an antimicrobial efficacy claim.

Clyra CEO Steve Harrison noted the technology addresses critical dimensions of wound care without tradeoffs, with particular relevance for veterans and service members treated in government facilities.

Key Assets and Next Catalysts

Clyra's portfolio includes the recently launched ViaCLYR and the upcoming Bioclynse surgical irrigation solution. First-half revenue reached US$154,000.

BioLargo's other platforms include ONM Environmental, serving municipal and industrial odor control customers, BLEST engineering services generating US$1.888 million in first-half revenue, and water treatment technology operating at a New Jersey site for over 10,000 hours.

BioLargo Energy Technologies continues development of its Cellinity battery with no revenue recorded yet.

Broader Sector Timing and Market Growth

The global wound care market is projected to grow from US$22.22 billion in 2025 to US$30.48 billion by 2030 at a 6.5% CAGR, driven by chronic conditions, surgical procedures, and aging populations.

The antimicrobial wound cleanser segment is expected to reach US$869.99 million by 2035. Hospitals represent about 52% of that segment, aligning with Clyra's government healthcare focus.

Analyst Views and Valuation Context

¹Technical Analyst John Newell of John Newell & Associates issued a Speculative Buy rating in a March 11 report, citing Clyra's FDA clearance, patent portfolio, and measured commercialization approach across multiple cleantech markets.

Oak Ridge Financial Analyst Richard Ryan maintained a Buy rating, noting the hub-and-spoke subsidiary model helps manage risk while targeting high-growth areas.[OWNERSHIP_CHART-6976]

Share Structure and Near-Term Events²

Insiders and management own about 13.73% of BioLargo, with institutions holding 0.04% on a 13F basis.

Market capitalization stands at US$31.23 million with 328.73 million shares outstanding. The stock trades in a 52-week range of US$0.08 to US$0.23.

Key Investor Takeaways

Clyra secured an exclusive reseller agreement with Spartan Medical for government healthcare facilities and ECAT listing.
ViaCLYR is FDA 510(k)-cleared for wound cleansing and irrigation with company-reported antimicrobial performance data.
The agreement forms Clyra's third distribution channel alongside U.S. and 18-country international partners.
BioLargo's broader portfolio spans medical, water treatment, odor control, and engineering, with first-half revenues reported across units.
The wound care market is expanding at 6.5% CAGR through 2030, supporting demand for advanced cleansing solutions.
Analysts maintain Buy and Speculative Buy ratings, citing commercialization strategy and multi-market exposure.

Common Questions from Investors

What does the Spartan Medical agreement provide? It grants Clyra an exclusive channel into U.S. government healthcare buyers through the ECAT catalog, covering VA/DoD, Federal Bureau of Prisons, Indian Health Service, and certain VA-funded civilian facilities.

What is ViaCLYR approved for? The FDA 510(k) clearance covers cleansing, irrigating, and debriding wounds such as burns, ulcers, and post-surgical sites, plus moistening dressings. Antimicrobial performance claims come from company testing.

How does this fit Clyra's rollout timeline? Spartan becomes the third reseller alongside existing U.S. and international partners. Manufacturing scale-up continues ahead of the Bioclynse surgical product launch next year.

What other BioLargo units are generating revenue? BLEST engineering posted US$1.888 million in first-half revenue, while ONM Environmental continues municipal and industrial sales under recurring contracts.

BioLargo continues executing across its cleantech platforms with the Spartan Medical channel providing a concrete step forward in the medical segment.

Important Disclosures:

BioLargo Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc. and Clyra Medical Technologies.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosure for the quote from the John Newell article published on March 11, 2026

For the quoted article (published on March 11, 2026), BioLargo paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.

Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: BLGO:OTCQX, )

Sernova-Seraxis Merger to Create BetaNova with US$10M for T1D Islet Trial

Wed, 09 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/09/2026

Sernova and Seraxis have entered into a definitive agreement to merge and create BetaNova Biotherapeutics, with US$10 million in financing to advance stem cell-derived islet therapy for type 1 diabetes, targeting Phase 1/2 data by mid-2027.

Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and Seraxis Holdings Inc. have signed a definitive merger agreement that will create BetaNova Biotherapeutics, a clinical-stage company developing stem cell-derived islet cell therapies for type 1 diabetes, according to a September 8 release.

The transaction includes a committed US$10 million non-brokered convertible note financing from existing insiders, open to other qualified investors through September 30. This capital directly supports cGMP manufacturing of SR-02, the start of a Phase 1/2 clinical trial in the first quarter of 2027, and initial data readout by mid-2027.

Why the BetaNova Merger Matters for Investors Now

Type 1 diabetes affects roughly 2.1 million people in the United States alone. Current treatments require lifelong insulin therapy and carry risks of severe complications.

BetaNova combines two complementary platforms that target the root cause: loss of insulin-producing islet cells.

Combined Technology Platform Creates Differentiated Position

BetaNova will integrate Sernova's Cell Pouch Bio-hybrid Organ, an implantable and retrievable device that has already demonstrated successful engraftment in a completed Phase 1/2 study with donor-derived islets, with Seraxis' stem cell-derived pancreatic islet cells.

The lead program SR-02 uses allogeneic stem cell-derived islets paired with lower-toxicity immunosuppressants. The follow-on SR-03 program incorporates gene edits expected to eliminate immunosuppression through immune evasion.

Key Development Milestones Backed by Financing

The US$10 million financing is allocated to four near-term priorities: cGMP production of SR-02 cells, initiation of the Phase 1/2 T1D trial in Q1 2027, preparation for a Nasdaq listing in Q1 2027, and advancement of an investigational new drug application for SR-03 in the second half of 2027.

The merger itself is expected to close in November 2026.

Orphan Drug Designation Adds Strategic Optionality

In June, Sernova received FDA orphan drug designation for autologous islet transplantation using the Cell Pouch to prevent diabetes after total pancreatectomy. The designation is for autologous islet transplantation to prevent diabetes following total pancreatectomy, a potential treatment approach for type 3c diabetes. If ultimately approved, an orphan-designated product may qualify for seven years of U.S. market exclusivity, along with other incentives such as certain tax credits and potential fee exemptions.

It extends the platform beyond type 1 diabetes without diverting focus from the primary T1D program.

Diabetes Market Growth Provides Broad Tailwinds

The global diabetes drug market is projected to rise from US$101.48 billion in 2025 to US$283.36 billion by 2034, expanding at an 11.80% CAGR, according to Fortune Business Insights.

North America accounts for nearly half of the current revenue. More than 40 million Americans live with diabetes, and an additional 115 million have prediabetes, according to the Centers for Disease Control and Prevention.

Analyst Reaction and Valuation Context

H.C. Wainwright reiterated a Buy rating on Sernova while lowering its price target to CA$1 from CA$6. The adjustment reflects updated share counts and the shift to earlier-stage Seraxis programs rather than any change in scientific outlook.

The firm described the merger rationale as a good move that pairs the Cell Pouch with scalable manufacturing and immune-evasion approaches. It noted blockbuster potential for SR-02 and SR-03 launches targeted for 2032 and 2033, while highlighting that the clinical performance of Seraxis cells inside the Cell Pouch remains to be demonstrated.

Key Investor Takeaways

The merger creates a single integrated platform combining proven device engraftment data with stem cell manufacturing scale.
US$10 million insider-backed financing funds the first clinical data readout by mid-2027.
Orphan drug designation provides potential exclusivity in type 3c diabetes as a secondary opportunity.
One analyst views the deal as strategically sound despite the reduced price target tied to dilution and program timing.
The combined company is expected to remain listed on the TSX, subject to applicable listing requirements and final TSX approval, and intends to seek a Nasdaq listing in Q1 2027.
Retail investors should monitor the November 2026 closing and the Q1 2027 trial initiation as near-term catalysts.

Ownership and Share Structure¹

About 10.74% of Sernova before the merger is held by insiders and management, and about 0.04% by institutions. The rest is retail. [OWNERSHIP_CHART-4790]

Top shareholders include Director Steven Sangha with 10.51%, Chief Financial Officer James Parsons with 0.16%, CEO Rigby with 0.06%, and CATAM Asset Management AG with 0.04%.

Sernova has 377.64 million outstanding shares. Its market cap is approximately CA$56.65 million. Its 52-week range is CA$0.10−CA$0.20 per share.

Common Questions from Investors

How will ownership be split after the merger? Sernova and Seraxis shareholders are each expected to own approximately 50% of BetaNova.

What is the status of the Cell Pouch technology? Sernova has already completed its Phase 1/2 study in type 1 diabetes, with all primary and secondary endpoints met and more than 30 years of cumulative safety data.

When could the first clinical data from the merged company appear? Initial Phase 1/2 dosing of SR-02 is planned for Q1 2027, with data expected by mid-2027.

Does the financing dilute existing shareholders immediately? The convertible notes convert automatically upon merger closing into non-voting shares that are subject to beneficial ownership limits before conversion to voting shares.

BetaNova will be headquartered in Germantown, Maryland, with integrated cGMP capabilities. The companies will hold a webinar on September 11 at 10 a.m. ET. Novo Nordisk (NVO:NYSE), Eli Lilly and Co. (LLY:NYSE), and Sanofi SA (SNY:NYSE) continue to dominate the broader diabetes market, yet the BetaNova approach targets a functional cure rather than ongoing symptom management.

Important Disclosures:

Sernova Biotherapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Biotherapeutics Inc.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: SVA:TSX; SEOVF:OTCQB; PSH0:XETRA, )

Biotechs Combine to Target Type 1 Diabetes Treatment

Tue, 08 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/08/2026

Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) has agreed to merge with privately held Seraxis to form BetaNova Biotherapeutics, a U.S.-based company advancing cell therapies for type 1 diabetes. Find out why one analyst calls the combination a good strategic move.

Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and private company Seraxis Holdings Inc. have entered into a definitive agreement to merge their businesses and technologies, creating BetaNova Biotherapeutics, a U.S.-based clinical-stage biotechnology company focused on developing a new approach to islet cell replacement for type 1 diabetes (T1D), according to a September 8 release.

BetaNova will be headquartered in Germantown, Maryland, with integrated research laboratories and cGMP (current Good Manufacturing Practice) capabilities, the release said. Shareholders of Sernova and Seraxis are expected to each hold approximately 50% of the combined company.

The transaction is supported by commitments for a US$10 million non-brokered convertible note financing from existing insider shareholders of both companies. The financing will remain open to other qualified investors through September 30. Once the merger closes, the notes will automatically convert into non-voting BetaNova common shares, which holders may convert into voting shares subject to beneficial ownership restrictions.

The financing is expected to fund several key development milestones, including cGMP production of SR-02 stem cell-derived pancreatic islet cells; initiation of a Phase 1/2 T1D clinical trial in the first quarter of 2027, with initial data expected by mid-2027; preparation for a Nasdaq listing during the first quarter of 2027; and continued development of an investigational new drug application for SR-03 in the second half of 2027.

BetaNova's lead candidate, SR-02, is an allogeneic stem cell-derived pancreatic islet therapy designed for use with next-generation, lower-toxicity immunosuppressants, with the longer-term objective of establishing immune tolerance and eliminating chronic immunosuppression, according to the release. Its follow-on candidate, SR-03, incorporates gene edits intended to enable immune evasion and potentially remove the need for immunosuppression.

The combined pipeline will also draw on Sernova's clinical work with its Cell Pouch Bio-hybrid Organ, an implantable and retrievable device designed to support the survival, engraftment, and function of pancreatic islet cells. Sernova has completed patient treatment and follow-up in its Phase 1/2 study involving donor-derived pancreatic islets in people with T1D, with all primary and secondary endpoints achieved and more than 30 years of cumulative patient safety data supporting the platform.

"This merger is deeply personal to me — I've lived with and suffered from type 1 diabetes most of my life, and it drives my passion to overcome it," said Jonathan Rigby, president and chief executive officer of Sernova and proposed CEO of BetaNova. "People with T1D struggle to manage the life-altering loss of insulin production, often resulting in serious co-morbidities. Combining Sernova's Cell Pouch Bio-hybrid Organ with Seraxis' stem cell-derived pancreatic islet cells lets us approach the problem differently, bringing us closer to a functional cure. This is very exciting to me and our entire team."

Will Rust, PhD, president and CEO of Seraxis and proposed president and chief scientific officer of BetaNova, said the combined platform addresses several hurdles that have limited islet cell replacement, including scalable manufacturing, successful engraftment, and protection of transplanted cells from immune attack.

BetaNova will bring together Seraxis' stem cell-derived islets, manufacturing capabilities, and immune-evasion strategy with Sernova's Cell Pouch Bio-hybrid Organ, an implantable and retrievable device designed to support islet cell survival, engraftment, and function.

Noble Capital Markets Inc. served as exclusive financial adviser to the merger, the release said. The companies will hold a webinar on September 11 at 10 a.m. ET to discuss the definitive agreement.

Sernova Wins Orphan Drug Designation for Cell Pouch Approach

In June, Sernova announced it had received U.S. Food and Drug Administration orphan drug designation for autologous islet transplantation (AIT) to prevent diabetes following total pancreatectomy. The designation supports the company's development of its Cell Pouch Bio-hybrid Organ as a potential treatment for type 3c diabetes (T3cD), a condition that can develop after pancreatic removal and shares characteristics and complications with type 1 diabetes.

Sernova's Cell Pouch is designed to provide an environment where transplanted therapeutic cells can establish a blood supply and continue functioning. The planned approach would use insulin-producing islet cells taken from a patient's own removed pancreas and implanted into the vascularized Cell Pouch, with the goal of maintaining insulin production after surgery while avoiding immunosuppressing drugs.

Dr. Melena Bellin, co-director of the Total Pancreatectomy and Islet Autotransplant Program at the University of Minnesota and a member of Sernova's Clinical Advisory Board, said the therapy could address the immediate loss of pancreatic endocrine function that follows total pancreatectomy.

"Patients who require total pancreatectomy face a life-changing outcome: the immediate loss of pancreatic endocrine function and the risk of complex, insulin-dependent diabetes," she said. "Autologous islet transplantation in Sernova's Cell Pouch has the potential to preserve a patient's own insulin-producing cells following pancreatic surgery, without the use of immune-suppressing therapies."

The FDA's orphan drug designation applies to therapies targeting rare diseases or conditions affecting fewer than 200,000 people in the United States and can provide several development benefits. For Sernova, these may include seven years of U.S. market exclusivity following approval, potential tax credits for eligible clinical testing, and possible exemptions from certain FDA user fees.

"Receiving Orphan Drug Designation from the FDA is an important milestone for Sernova," Rigby said at the time. "Our primary focus remains on advancing a functional cure for type 1 diabetes. At the same time, this designation provides Sernova a potential exclusive lead position in preventing type 3c diabetes. T3cD is a natural extension of our primary focus on T1D, and we are planning to advance."

Wainwright Keeps Buy, Trims Target on Merger Math

In an updated September 8 research note, H.C. Wainwright & Co. reiterated its Buy rating on Sernova Corp. while lowering its price target to CA$1 from CA$6, after the company agreed to merge with privately held Seraxis to create the new company.

The firm attributed the lower target mainly to updated fully diluted share counts and to swapping its Cell Pouch projections for the merged company's earlier-stage Seraxis programs, rather than a dimmer view of the science. Sernova and Seraxis shareholders would each own about 50% of BetaNova, insiders of both have committed to a US$10 million convertible note financing, and the deal is expected to close in November 2026. The combined company is expected to remain listed on the TSX and intends to seek a Nasdaq listing in the first quarter of 2027, subject to applicable listing requirements and approvals.

The report framed the combination as strengthening an integrated diabetes platform, pairing Sernova's Cell Pouch implant with Seraxis' stem cell-derived pancreatic islets and in-house cGMP manufacturing.

"We view the strategic rationale for the merger as a good move, as the combination brings together Sernova's Cell Pouch with Seraxis' stem cell-derived pancreatic islets, in-house cGMP manufacturing capabilities, and approaches aimed at reducing or eliminating chronic immunosuppression," the report said.

The near-term catalyst is BetaNova's lead candidate, SR-02, an allogeneic stem cell-derived islet therapy with an FDA-cleared IND, with initial Phase 1/2 dosing expected in the first quarter of 2027 and data by mid-2027. The firm flagged one key unknown — whether Seraxis' cells will perform inside the Cell Pouch.

"The clinical performance of Seraxis' cells in combination with the Cell Pouch has yet to be reported," the report said, while describing both SR-02 and the follow-on SR-03 as carrying blockbuster potential for projected 2032 and 2033 launches.

The Catalyst: Diabetes Drug Market Heading Toward US$283 Billion

More than 40 million Americans, about 12% of the population, are living with diabetes, according to the Centers for Disease Control and Prevention. Of the roughly 40.1 million people with the disease, 29.1 million are diagnosed, and about 11.0 million, or 27.6% of adults with diabetes, remain undiagnosed. Prevalence rises sharply with age, reaching 28.8% among Americans 65 and older, and another 115.2 million U.S. adults are living with prediabetes.

By type, the CDC data show Type 2 diabetes accounts for 90% to 95% of all diagnosed adult cases, while Type 1 diabetes affects about 2.1 million people, including 314,000 children and adolescents.

The global diabetes drug market is expected to expand significantly, increasing from US$101.48 billion in 2025 to US$116.11 billion in 2026 and reaching US$283.36 billion by 2034, according to Fortune Business Insights. The market is projected to advance at an 11.80% CAGR during the forecast period, with North America accounting for 49.95% of global revenue in 2025. Novo Nordisk (NVO:NYSE), Eli Lilly and Co. (LLY:NYSE), and Sanofi SA (SNY:NYSE) are among the major companies driving the sector.

Diabetes remains a growing worldwide health challenge. The International Diabetes Federation estimates that 537 million adults were living with the disease in 2021, with that total expected to reach 643 million by 2030 and 783 million by 2045. Beyond its health effects, diabetes creates a substantial economic burden through related complications, reduced quality of life, and shortened life expectancy.[OWNERSHIP_CHART-4790]

Market growth is being supported by the increasing incidence of diabetes, population aging, and improvements in drug delivery. Treatments for type 1 and type 2 diabetes include insulin, GLP-1 receptor agonists, and SGLT2 inhibitors, which can be delivered orally, intravenously, or through subcutaneous administration to help control blood glucose levels.

Ownership and Share Structure¹

About 10.74% of Sernova before the merger is held by insiders and management, and about 0.04% by institutions. The rest is retail.

Top shareholders include Director Steven Sangha with 10.51%, Chief Financial Officer James Parsons with 0.16%, CEO Rigby with 0.06%, and CATAM Asset Management AG with 0.04%.

Sernova has 377.64 million outstanding shares. Its market cap is approximately CA$56.65 million. Its 52-week range is CA$0.10−CA$0.20 per share.

Common Investor Questions

What did Sernova announce? Sernova Biotherapeutics Inc. signed a definitive agreement to merge with privately held Seraxis Holdings Inc. to create BetaNova Biotherapeutics, a U.S.-based clinical-stage company developing a new approach to islet cell replacement for type 1 diabetes, according to a September 8 release.

What is BetaNova, and who will own it? BetaNova will be headquartered in Germantown, Maryland, with integrated research labs and cGMP manufacturing. Sernova and Seraxis shareholders are each expected to own about 50% of the combined company, which is expected to remain listed on the TSX and to pursue a Nasdaq listing in the first quarter of 2027.

How is the merger being financed? The transaction is backed by commitments for a US$10 million non-brokered convertible note financing from insiders of both companies, open to other qualified investors through September 30. On closing, the notes automatically convert into non-voting BetaNova shares, convertible to voting shares subject to ownership limits. The financing is meant to fund SR-02 manufacturing, the Phase 1/2 trial, Nasdaq listing preparation, and SR-03 development.

What are the lead programs? BetaNova's lead candidate, SR-02, is an allogeneic stem cell-derived pancreatic islet therapy meant to be used with lower-toxicity immunosuppressants, with the longer-term goal of eliminating chronic immunosuppression. Follow-on candidate SR-03 adds gene edits intended to enable immune evasion. Both would draw on Sernova's Cell Pouch, an implantable, retrievable device that supports transplanted islet cells; Sernova has completed its Phase 1/2 Cell Pouch study in T1D with all primary and secondary endpoints met and more than 30 years of cumulative patient safety data.

What was the June orphan drug designation? In June, Sernova received FDA orphan drug designation for autologous islet transplantation to prevent diabetes following total pancreatectomy, supporting the Cell Pouch as a potential treatment for type 3c diabetes. The designation can bring up to seven years of U.S. market exclusivity after approval, tax credits for eligible testing, and possible user-fee exemptions.

What do analysts say? H.C. Wainwright & Co. reiterated a Buy while lowering its target to CA$1 from CA$6, attributing the cut mainly to updated fully diluted share counts and to substituting the earlier-stage Seraxis programs for its Cell Pouch projections, not a dimmer view of the science. It called the strategic rationale "a good move" but flagged that the performance of Seraxis' cells inside the Cell Pouch has not yet been reported.

What are the key milestones ahead? The merger is expected to close in November 2026, subject to shareholder approval. Initial Phase 1/2 dosing of SR-02 is expected in the first quarter of 2027, with data by mid-2027; an SR-03 IND is targeted for the second half of 2027; and a Nasdaq listing is planned for the first quarter of 2027.

Important Disclosures:

Sernova Biotherapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Biotherapeutics Inc.
Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: SVA:TSX; SEOVF:OTCQB; PSH0:XETRA, )

Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone

Thu, 10 Sep 2026 00:00:00 PST

Source: Stewart Thomson 09/10/2026

Technical Analyst Stewart Thomson reviews Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) following its achievement of a major regulatory milestone.

Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) is a Canadian healthcare company planning to build a national network of brain-specific PET scanning clinics, targeting a US$9.2 billion Alzheimer's diagnostics market that is projected to reach US$10.2 billion in 2026. Each NovaScan Neuroimaging Clinic™ uses an FDA-cleared CareMiBrain scanner.

There are plans to scale to 200 locations nationally. Following its April 2026 rebrand from Algernon Health and a 10:1 share consolidation, the imaging clinic business is planned to be a near-term cash generator, with a legacy drug pipeline providing longer-term optionality.

In June of this year, Grey Matters closed a CA$1.25M private placement to fund its first U.S. clinic. In July, it took delivery of the first FDA-cleared CareMiBrain™ system for its Davie clinic, featuring brain-only imaging with 25% less radiation and a seated patient design.

On August 19, Grey Matters announced it has signed a professional services agreement with ProScan Reading Services, a nationally recognized neuroradiology firm, to interpret brain PET scans.

A day later, the company received its Radioactive Materials License from the State of Florida, which is the last major regulatory step needed for a clear path to scan the first patient by September 30. The charts show the bulls are taking control, and a revaluation of the company appears warranted.

Grey Matters announced on September 10, 2026, the closing of the first tranche (the "First Tranche") of its non-brokered private placement previously announced on August 20, 2026.

Gross Proceeds from the First Tranche total CA$600,000, consisting of CA$285,000 from the sale of 712,500 units at CA$0.40 and CA$315,000 from the sale of unsecured convertible debenture units.

Why Healthcare?

Investing in healthcare offers a unique combination of defensive stability and long-term growth potential, driven by essential, non-discretionary demand that remains resilient during economic downturns.

The sector has historically provided consistent earnings growth and lower volatility compared to broader markets, making it a critical tool for portfolio diversification and protection against inflation.

Figure 1: IYC:NYSE US Healthcare ETF Chart

Technical Analysis & Observations:

A ten-year uptrend is evident.
Volume is supportive, rising on rallies.
The Stochastics momentum oscillator is on a buy signal.
The CMF money flows indicator is in bull mode.
OBV (on balance volume) is confirming the price action, hitting record highs.
Moving averages are bullish.

Fundamental Share Price Catalysts

Davie Clinic Opening (Q3 2026): The first U.S.-dedicated brain PET clinic is imminent, with major licenses secured and the CareMiBrain system installed. The company says its scans are covered by Medicare, Medicaid, and private insurance, with a minimum reimbursement figure of US$4,500 per scan cited in its investor materials.
Catalyst MedTech Partnership: Catalyst MedTech is the exclusive U.S. distributor of CareMiBrain under a more than CA$4 million supply, financing, and services agreement with the company.
PET Scans: Separately, Grey Matters signed a non-binding LOI for an Alzheimer's clinical trial at a planned second location in Tampa. The non-binding LOI for a minimum of 200 PET scans could provide an initial revenue opportunity if converted into a definitive services agreement.
200-Clinic U.S. Network: Management plans a national network of 200 NovaScan locations, each requiring approximately US$1.1 million in capital. Partnerships with GE HealthCare (tracer supply) and ProScan Reading Services (radiology interpretation) de-risk operational execution.
Structural Demand Tailwind: Two FDA-approved monoclonal antibody treatments for Alzheimer's require a positive beta-amyloid PET scan before therapy can begin, creating a durable, growing demand driver. Approximately 158 Alzheimer's drug candidates are currently being evaluated in clinical trials, creating a potential market for brain PET imaging services as drug programs advance.
Legacy Drug Pipeline: Repirinast (NP-251) for chronic kidney disease and a proprietary DMT program for stroke/TBI recovery remain active, alongside a 20% equity stake in Seyltx (Ifenprodil for chronic coughs).

Grey Matters Versus Competitors

Large imaging networks: RadNet (RDNT:NASDAQ) offers PET/CT as one service among many, but Grey Matters' brain-dedicated, seated-patient, lower-radiation model is a differentiated experience no large network currently offers.
Regional PET specialists: The PET Imaging Institute of South Florida operates in the Fort Lauderdale/Hollywood area but uses conventional PET/CT equipment. Grey Matters says its Davie Clinic will be the first in the U.S. to offer brain-dedicated PET scanning using the CareMiBrain system
Academic medical centers: Massachusetts General Hospital and peers set clinical standards for amyloid PET, but their research-focused model makes them poorly positioned as accessible, patient-friendly outpatient clinics, which is the gap Grey Matters is built to fill.

[OWNERSHIP_CHART-9895]

Ownership and Share Structure

Management and insiders own about 11 percent of the company, and about 21 percent is owned by institutions. The rest is with retail. Top shareholders include Alpha North Asset Management with 20.52 percent, Chief Executive Officer Christopher Moreau with 5.05 percent, Chairman of the Board Harry Bloomfield with 1.97 percent, Chief Financial Officer James Kinley with 1.4 percent, and Director Rajpaul Attariwala with 1.2 percent.

Grey Matters has approximately 9.81 million shares outstanding, a market cap of CA$5.4 million, and a 52-week range of CA$0.335–CA$0.68.

Technical Analysis

Figure 2: Grey Matters Weekly Chart

Technical Analysis and Observations:

A bull wedge with a burst of volume at the base of the wedge is in play.
Stochastics is flashing a crossover buy signal.
Money flow indicators MFI and OBV are surging.
RSI is bullish.

Figure 3: Grey Matters Versus CDNX Chart

Technical Analysis and Observations:

Grey Matters is a CDNX component stock. Money managers look for stocks that can outperform the index, and Grey seems ready to do that now.
There's a bull wedge, and it's morphed into a rectangular base pattern.
Stochastics is on a buy signal.

Investor Risks

Execution & Capital: The company is pre-revenue with a ~CA$5.4 M market cap; the Davie clinic must open on schedule and generate patient volume. US$220M+ capital is needed for a 200-clinic rollout.
Dilution: Ongoing private placements and warrant issuances could continue to dilute existing shareholders as the company funds each new clinic.
Concentration & Competitive Entry: The imaging business is heavily dependent on a single partnership (Catalyst MedTech) and a single platform (CareMiBrain); established imaging networks could replicate the brain-specific PET model once the market validates the concept.
Professional Advice: Before taking action with any investment, investors should consult with properly licensed, experienced, and qualified investment advisors and get numerous opinions. Failure to do so increases risk.

Investment Thesis Summary

First-Mover Advantage in U.S. Brain-Dedicated PET: Grey Matters is building the first network of purpose-built brain PET clinics in the U.S., with no direct competitor currently offering a seated, lower-radiation, brain-only scanning experience at scale.
Structural Demand Tailwind: Two FDA-approved Alzheimer's monoclonal antibody treatments require confirmation of beta-amyloid pathology by brain PET or another approved biomarker method, such as cerebrospinal fluid testing, before treatment. The growing Alzheimer's drug-development pipeline could create additional demand for PET-based patient screening and clinical-trial imaging.
De-Risked Near-Term Path to Revenue: The Florida Radioactive Materials License, CareMiBrain scanner delivery, ProScan reading agreement, and the separate 200-scan Catalyst MedTech LOI for the planned Tampa location collectively advance the company toward its first patient and subsequent clinic expansion.
Scalable Unit Economics: Each clinic is expected to generate revenue from eligible PET scans reimbursed by Medicare, Medicaid, and private insurers.
Additional Optionality from Legacy Pipeline: Repirinast for CKD, the DMT program for stroke/TBI, and a 20% equity stake in Seyltx (Ifenprodil for chronic cough) provide upside beyond the imaging core at no incremental cost to shareholders.
Bullish Charts: Charts for the global healthcare sector and Grey Matters are both bullish.

Conclusion

Grey Matters has cleared major hurdles, including licensing and clinical LOI. Potential patient revenues by September 30 are a near-term catalyst. Two FDA-approved Alzheimer's therapies require confirmation of beta-amyloid pathology by brain PET or spinal tap before treatment, and the growing Alzheimer's drug-development pipeline could create additional demand for PET-based screening and clinical-trial imaging.

Grey Matters is positioned at the intersection of that demand with a differentiated, lower-radiation, seated-patient experience that no large network currently offers. Even partial execution of the 200-clinic plan transforms this pre-revenue company into a national diagnostics platform, and the bullish stock charts imply a significant re-rating of the company could be imminent.

Stock price at time of writing (September 8, 2026): CA$0.55

Resistance Zones for Investor Profit Booking

Short-Term: CA$0.85

Medium-Term: CA$1.20

Long-Term: CA$1.65

Technical Rating: Speculative Buy

Important Disclosures:

Grey Matters Health Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship. In addition, Grey Matters Health Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000
Grey Matters Health Inc. has paid Street Smart (an affiliate of Streetwise Reports) a fee of US$3,000 for the preparation of an independent technical research report.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health Inc.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. Mr. Thomson is not an investment advisor. He does not know the financial situation or risk tolerance of any reader. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed. Mr. Thomson owns no securities in Grey Matters Health Inc., and he has no direct financial relationship with the company.
Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services, or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: GREY:CSE; AGNPF:OTCQB; AGW0:FSE, )

Cleantech Firm Expands Breakthrough Wound Solution to Veterans

Thu, 10 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/10/2026

BioLargo Inc. (BLGO:OTCQX) is bringing its FDA-cleared ViaCLYR wound solution to U.S. government and VA-contracted healthcare facilities through a new deal with Spartan Medical.

Cleantech and life sciences company BioLargo Inc. (BLGO:OTCQX) announced that its subsidiary Clyra Medical Technologies has entered an exclusive agreement with Spartan Medical Inc. to resell its FDA-cleared ViaCLYR™ advanced wound irrigation solution to government healthcare facilities worldwide, according to a September 3 release. The company said the agreement establishes a dedicated commercial channel serving U.S. government healthcare facilities.

"This third reseller agreement for Clyra's ViaClyr opens a direct path for federal government purchasing and distribution," BioLargo Chief Executive Officer Dennis Calvert said in the release. "Together with its existing U.S. distributor Advanced Solution LLC, and an international distribution agreement with Al Hikma covering 18 countries, Spartan Medical's government healthcare channel strengthens Clyra's commercial rollout and supports revenue growth as it scales manufacturing ahead of the anticipated national launch of its surgical product next year."

The agreement brings Clyra's Clyrasept™ Copper-Iodine Complex Solution (CICS) to healthcare facilities where wound care remains a key clinical concern, according to the release.

ViaCLYR, powered by Clyrasept, is "the first-ever, broad-spectrum antimicrobial optimized for speed, efficacy, persistence, and biocompatibility," the company said. In clinical tests cited in the release, ViaCLYR killed 99.9999% of 18 pathogens within one minute of application and is "proven effective against MRSA, VRE, and Candida auris," the company said. ViaCLYR provides persistent 72-hour antimicrobial management without reapplication and, because it is non-cytotoxic, does not require rinsing, the release said. By comparison, the company said, standard wound care solutions have fast kill times but persist for 60 seconds or less and require regular, repeated reapplication and wound dressing changes. The performance figures reflect company-reported testing; ViaCLYR's FDA 510(k) clearance covers cleansing, irrigating, and debriding wounds, not an antimicrobial efficacy determination.

"Our groundbreaking technology was developed to address the four critical dimensions of wound care and infection control without compromise or tradeoffs," said Clyra Chief Executive Officer Steve Harrison. "We are proud to partner with the Spartan team to bring better care to those who have bravely and proudly served our country. We are confident that ViaCLYR will quickly become the standard of care across the VA, military, and government healthcare continuum."

Clyra's ViaCLYR Added to Defense Logistics Agency Catalog

ViaCLYR is FDA 510(k)-cleared for cleansing, irrigating, and debriding a wide range of wound types, including first- and second-degree burns, Stage I-IV pressure ulcers, diabetic and stasis ulcers, post-surgical wounds, and abrasions, as well as for moistening and lubricating absorbent wound dressings, the release noted.

"Adding ViaCLYR to our product portfolio brings a game-changing solution to a persistent challenge faced by every facility we serve," said Vince Proffitt, president of Spartan Medical. "By offering parity pricing for a clearly superior product, Clyra is demonstrating a commitment to improving the care and long-term well-being of countless veterans, service members, and individuals treated in our government healthcare facilities."

ViaCLYR has now been added to the Defense Logistics Agency Electronic Catalog (ECAT) and is available for resale to Government healthcare facilities, including VA/DoD-operated or -managed facilities, Federal Bureau of Prisons facilities, Indian Health Service facilities, and other federal agency healthcare facilities, as well as certain civilian hospitals operating under VA Community Care/VA-funded contracts, Clyra said in the release.

Spartan Medical is a veteran-owned and operated government contractor serving the U.S. Department of Veterans Affairs, the U.S. Department of Defense, and other local, state, and federal agencies. Its senior executives bring leadership experience from both public and private-sector organizations, while the company focuses on addressing complex challenges through creative thinking, innovative solutions, and flexible, highly skilled teams.

Spartan Medical provides medical facilities with comprehensive solutions designed to improve patient care and outcomes, with a particular focus on U.S. military and veteran communities, the release said.

BioLargo Advances Its Businesses Toward Commercial Scale

BioLargo is advancing several business platforms toward commercialization, led by Clyra. ViaCLYR landed its first U.S. distributor order in February 2026 and an 18-country distribution deal with Dubai's Al-Hikma FZCO in May, while it booked US$154,000 in first-half revenue. Its next product, the surgical-irrigation solution Bioclynse, is slated to launch through a national distribution counterparty — extending the technology toward surgical use.

On the consumer side, the newly formed BioLargo CPG LLC plans an October relaunch of CupriDyne®-based household products, this time with BioLargo owning the brand and controlling the chain end to end, after the Pooph, Inc. license was revoked in September 2025. Its ONM Environmental unit keeps selling CupriDyne Clean and the equipment used to deploy it to municipalities, landfills, and industrial customers, supported by recurring Southern California contracts.

BioLargo Engineering, Science & Technologies (BLEST) generated US$1.888 million in first-half revenue — including roughly US$100,000 a month from U.S. Air Force air-quality work — and was awarded a US$1.2 million contract in April to design a pilot-scale minerals processing facility for the remediation and beneficial reuse of a legacy mineral-waste deposit in the western U.S.

In water treatment, BioLargo's Aqueous Electrostatic Concentrator has run at Lake Stockholm, New Jersey, for more than six months (10,000-plus hours), removing PFAS to state and federal limits while undergoing EPA and state testing. And BioLargo Energy Technologies is developing Cellinity, a long-duration liquid-sodium battery built on abundant domestic materials with a projected 20-plus-year life — now in customer and financing talks, but with no formal project financing agreements or factory development contracts and no revenue yet.

"We have important milestones that we expect to accomplish over the next six to nine months," Calvert said last month. "If those things happen, the thesis is working. If any of them do not, we will say so plainly and tell you why."

BioLargo will hold its stockholder town hall on September 10 at 1 p.m. Pacific (4 p.m. Eastern), where management plans to review second-quarter results and commercialization across its medical, water-treatment, odor-control, energy-storage, and engineering businesses.

Expert: Portfolio Covers Multiple Cleantech Markets

¹Technical Analyst John Newell of John Newell & Associates examined BioLargo's healthcare business through its Clyra Medical Technologies subsidiary in a March 11 report for Streetwise Reports. Newell said BioLargo has followed a measured commercialization strategy, first putting its proprietary technologies through rigorous scientific testing before leveraging established partners to broaden its market presence. He pointed to the company's diverse portfolio, which includes water treatment, environmental remediation, air-quality technologies, energy storage, and medical applications.

Newell identified Clyra as one of BioLargo's key healthcare assets, citing its copper-iodine technology, which has an antimicrobial component that functions as a preservative in the solution without causing cytotoxic effects. Newell also highlighted ViaCLYR's FDA 510(k) clearance, which allows the product to enter established medical-device distribution channels, while noting that the underlying platform is backed by approximately 40 issued and pending patents covering liquid, powder, hydrogel, and antimicrobial dressing products.

Citing the potential across BioLargo's technology portfolio, Newell assigned the company a Speculative Buy rating. He said BioLargo's disciplined approach to commercialization, combined with its focus on strategic partnerships, could position the company to capitalize on rising demand for advanced healthcare technologies and sustainable energy-storage solutions.

Oak Ridge Financial Analyst Richard Ryan characterized BioLargo's business strategy in a May 18 report as a "hub and spoke format invent/acquire a product, prototype/prove it out, partner with necessary third parties, and commercialize." Ryan retained his Buy rating, saying the company's independent operating subsidiaries help distribute commercialization risk while enabling BioLargo to maintain substantial ownership interests in businesses targeting several rapidly growing markets.

The Catalyst: A Growing Wound Care Market Lifts Demand

The global wound care market is expected to expand from US$22.22 billion in 2025 to US$30.48 billion by 2030, representing a 6.5% CAGR, according to MarketsandMarkets. The research firm cited rising rates of chronic illnesses, an increase in traumatic wounds and burns, and greater healthcare needs among older populations as key drivers. With healthcare providers, insurers, and manufacturers focused on improving outcomes while reducing long-term costs, wound care is taking on greater importance across hospitals, outpatient centers, home healthcare, and long-term care facilities.

MarketsandMarkets also anticipates stronger demand for wound care products as providers manage growing numbers of chronic wounds, diabetic foot ulcers, pressure injuries, venous leg ulcers, surgical wounds, and trauma-related injuries. The report said delayed healing can drive up hospital costs, require more healthcare resources, and increase readmission rates, making effective wound management both a clinical necessity and a key tool for healthcare organizations seeking greater cost control and efficiency.

The timing lines up with a wound-cleansing market that is expanding steadily. In its Antimicrobial Wound Cleanser Market report, Towards Healthcare valued the segment at US$560.21 million in 2025 and US$585.42 million in 2026, projecting growth to US$869.99 million by 2035, a compound annual rate of 4.5% over the period.[OWNERSHIP_CHART-6976]

The firm tied that growth to the same clinical problems Clyra's products target. "The globally accelerating burden of surgical procedures, burns, and road accidents is propelling demand for advanced wound cleanser solutions," Towards Healthcare wrote, pointing as well to a heightened focus on reducing hospital-acquired and surgical-site infections. Rising rates of diabetes and obesity, it added, are driving more non-healing wounds that require advanced cleansing, with diabetic foot ulcers, pressure injuries, and venous leg ulcers expected to fuel the fastest-growing part of the market.

The report also underscores where such products are used: hospitals account for roughly 52% of the market, and acute wounds account for about 62%, the setting Clyra is targeting through its listing on the Defense Logistics Agency catalog and distribution to government and VA/DoD healthcare facilities. Clyra's next product, the surgical-irrigation solution Bioclynse, extends the same technology toward the surgical-site infection risk the report flags as a core demand driver.

Ownership and Share Structure²

About 13.73% of BioLargo is owned by insiders and management. About 0.04% is held by institutions with 13F-disclosed institutional holdings only. The rest is retail.

Its market cap is US$31.23 million, with about 328.73 million shares outstanding. It trades in a 52-week range of US$0.08 and US$0.23.

Common Investor Questions

What did BioLargo and Clyra announce? Clyra Medical Technologies, a subsidiary of BioLargo, entered an exclusive agreement with Spartan Medical to resell its FDA-cleared ViaCLYR advanced wound-irrigation solution to U.S. government healthcare facilities worldwide. ViaCLYR has also been added to the Defense Logistics Agency's Electronic Catalog (ECAT).

What is ViaCLYR cleared to do? ViaCLYR is FDA 510(k)-cleared for cleansing, irrigating, and debriding a range of wound types, including first- and second-degree burns, Stage I-IV pressure ulcers, diabetic and stasis ulcers, post-surgical wounds and abrasions, and for moistening and lubricating absorbent dressings. That clearance covers the cleansing and irrigation function. The antimicrobial performance the company cites, such as killing 99.9999% of 18 pathogens in one minute and 72-hour persistence, comes from company-reported testing, not from an FDA efficacy determination, and its Clyrasept copper-iodine component is characterized as functioning as a preservative in the solution.

Why does the Spartan Medical deal matter? It gives Clyra an exclusive channel into federal healthcare buyers. Through the ECAT listing, ViaCLYR can be resold to VA/DoD facilities, Federal Bureau of Prisons and Indian Health Service facilities, other federal agency healthcare sites, and certain civilian hospitals under VA Community Care contracts. Spartan, a veteran-owned government contractor, is offering it at parity pricing.

How does this fit Clyra's broader rollout? Spartan is Clyra's third reseller arrangement, alongside U.S. distributor Advanced Solutions and an 18-country international agreement with Dubai's Al-Hikma FZCO. Clyra booked US$154,000 in first-half revenue and is scaling manufacturing ahead of the anticipated national launch of its surgical-irrigation product, Bioclynse, next year.

Important Disclosures:

BioLargo Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc. and Clyra Medical Technologies.
Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosure for the quote from the John Newell article published on March 11, 2026

For the quoted article (published on March 11, 2026), BioLargo paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: BLGO:OTCQX, )

Telehealth Platform Delivers 196% U.S. Visit Growth in Q2

Thu, 03 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/03/2026

Rocket Doctor AI reports 43% revenue growth and 196% U.S. patient visit increase in Q2 2026, backed by 24 million covered lives and an expanding payer network.

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) posted revenue of CA$734,028 for the second quarter ended June 30, 2026, up 43% from CA$512,756 in the same period of 2025.

Revenue was broadly consistent with the CA$737,103 reported in the first quarter of 2026. Completed U.S. patient visits rose 196% quarter over quarter to 3,911 from 1,319.

Why the Q2 Results Matter for Investors

The sharp rise in U.S. patient volume shows early traction from new in-network payer agreements. These contracts now provide access to roughly 24 million covered lives across California, Maryland, and New York State.

The company noted that some U.S. revenue is booked on a cash basis, so the full impact of higher visit counts will appear in later quarters.

Platform Advantages and Payer Footprint

Rocket Doctor built its digital health platform with physicians, which helps align tools with clinical workflows.

Active U.S. clinicians grew from 19 to 30 during the quarter, while 80 providers sit on the roster, with most advancing through credentialing.

In Canada, completed visits rose 23% year over year to 45,766.

Key Growth Assets and Near-Term Catalysts

During the quarter, the company added its first U.S. value-based primary care agreement and expanded coverage in Maryland. Post-quarter moves include SOC 2 Type 1 compliance, an extended EngageWell partnership in New York City, and additional in-network access for more than 100,000 members in New York. The firm also closed two tranches of convertible debenture financing for roughly CA$3.26 million.

Other second-quarter developments included a Digital Health Observership Program with the University of Toronto, a marketing partnership with Rick Ware Racing and FINTEKK AP, and a partnership with Mindstride AI to provide after-hours and overflow physician coverage in Ontario, Alberta, and British Columbia. Also during the quarter, Treatment.com, the U.S. subsidiary, secured US$250,000 in Year 2 NIH funding.

Telehealth Sector Timing

J.P. Morgan Payments described telehealth as part of a broader shift toward digitalized healthcare, with virtual care increasingly combining remote medical services, connected devices, and digital payment infrastructure. The firm cited Grand View Research, which valued the global telehealth market at US$83.5 billion in 2022, and McKinsey's estimate that US$250 billion of current U.S. healthcare spending has the potential to be virtualized.

A separate U.S. telehealth market report published in August by Market.us described virtual care as increasingly incorporated into routine healthcare delivery across primary care, chronic disease management, behavioral health, follow-up consultations, and specialty services.

Analyst Views and Valuation Context

¹Technical analyst Stewart Thomson highlighted Rocket Doctor AI's growing digital health platform on March 17, and rated the stock a Strong Speculative Buy with targets of CA$0.80 short term, CA$1.00 medium term, and CA$1.60 long term.

Fundamental Research Corp. analyst Sid Rajeev reiterated a Buy rating and CA$1.55 target on June 11, 2026, citing U.S. expansion and rising patient volumes.[OWNERSHIP_CHART-10594]

Share Structure and Liquidity²

Rocket Doctor AI Inc. has a market cap of approximately CA$59.61 million, with 101.04 million shares outstanding. The 52-week range is CA$0.50-CA$0.98.

Management and insiders own 4.24% of shares. Cash and cash equivalents stood at CA$0.95 million as of June 30, 2026.

Key Investor Takeaways

Q2 revenue rose 43% year over year to CA$734,028, while U.S. patient visits jumped 196% quarter over quarter.
In-network payer agreements now cover approximately 24 million lives in three states, with Florida and Texas in the expansion pipeline.
80 providers are on the roster, with the majority still advancing through credentialing, which could expand the company's clinical capacity as more providers become in-network.
Gross margin was 65% as the company scales its U.S. platform; timing differences in revenue recognition are expected to resolve in later quarters.
Post-quarter financing added roughly CA$3.26 million and new payer access for more than 100,000 members in New York.

Common Questions from Investors

What drove the 196% increase in U.S. patient visits?

The rise reflects new payer agreements and growth in the active clinician network from 19 to 30 during the quarter.

How many covered lives are included in the current U.S. network?

Approximately 24 million covered lives across California, New York, and Maryland.

When will the full revenue impact of higher U.S. visits appear?

Certain U.S. revenues are recognized on a cash basis, so the company expects the impact to be recorded in future quarters.

What states are next for U.S. expansion?

Management has identified Florida and Texas among the states in the expansion pipeline.

What is the Global Library of Medicine?

It is an AI knowledge base developed with more than 25,000 hours of input from hundreds of clinicians and more than 10,000 expert medical reviews, covering over 1,000 diseases and 17,000 symptoms for integration into telehealth and other systems.

The company continues to execute on U.S. payer relationships and physician onboarding while the broader telehealth market expands. Retail investors should monitor quarterly patient volumes, new payer signings, and credentialing progress as key milestones.

Important Disclosures:

Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: AIDR:CSE; AIRDF:OTC; 939:FRA, )

Rakovina Therapeutics Shifts 72% of Budget to AI Cancer Programs

Thu, 03 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/03/2026

Rakovina Therapeutics allocated 72% of its budget to AI-powered drug discovery in the second quarter of 2026, up from 57% in Q2 2025. See the three AI-supported DDR programs and upcoming milestones for retail investors.

Rakovina Therapeutics Inc. (RKV:TSX.V) raised the portion of its spending devoted to AI-powered drug discovery to 72% in the second quarter of 2026. The increase from 57% a year earlier shows a clear shift toward its three AI-supported cancer programs, while overall costs fell sharply.

The company cut its quarterly net loss by 41% to CA$1.73 million from CA$2.92 million in the same quarter of 2025. General and administrative expenses dropped 63% year over year to CA$450,695. Research and development spending reached CA$1.13 million in the quarter and CA$2.16 million for the first half of 2026.

Why the Budget Shift Matters for Investors Now

Lower overhead allowed more resources to flow into AI-driven discovery at a time when the broader biotech sector continues to face tight financing markets. Rakovina closed the second and final tranche of its upsized non-brokered private placement for total gross proceeds of CA$1.99 million after the quarter ended, subject to final acceptance by the TSX Venture Exchange, adding capital to support its ongoing programs.

Company Focuses on AI-Validated DNA Damage Response Therapies

Rakovina combines AI screening platforms with laboratory validation at the University of British Columbia and the Vancouver Prostate Centre.

This hybrid approach aims to speed the identification of selective inhibitors that target DNA damage response pathways in cancer cells.

Key Programs and Next Catalysts

The kt-5000AI program is developing a dual ATR/mTOR inhibitor designed for solid tumors, PTEN-deficient cancers, and CNS metastases. As of the latest update, 138 molecules had been predicted and 43 synthesized, with leads confirmed potent, selective, and CNS-penetrant in vivo. Planned 2026 milestones include additional in vivo data, lead optimization, and lead selection by year-end.

The kt-3000 program centers on kt-3283, a dual PARP/HDAC inhibitor that demonstrated superior preclinical activity versus selected approved agents. Work continues on a lipid nanoparticle formulation under a proposed joint venture with NanoPalm for targeted delivery. Milestones include joint-venture funding and formulation data at peer-reviewed meetings in 2026.

The kt-2000AI program is screening for a brain-penetrant PARP inhibitor aimed at breast, ovarian, and prostate cancers. Billions of compounds were evaluated through the Deep Docking platform, yielding leads with confirmed selectivity. Further AI output and lead candidate selection are scheduled for the fourth quarter of 2026.

At its annual general meeting, shareholders elected five directors and re-appointed the auditor. Dr. Petra Hamerlik joined the board while Jeffrey Bacha moved to an advisory role.

Broader Sector Timing and AI in Biotech

A June report from EY said biotech had recorded a third consecutive year of growth, with industry revenue rising more than 12% and financing reaching US$68.5 billion in 2025. AI-driven R&D was highlighted as one area positioned for continued innovation.

A February 24 review published in Oncol Res described DNA damage response as a central factor in tumor survival and therapy resistance. Next-generation inhibitors and nanocarrier delivery systems are being studied to improve selectivity and address resistance.

According to a research topic published by Frontiers on August 16, DDR research continues to explore vulnerabilities created by defects in cancer-cell repair pathways, with ongoing work on biomarkers and combination strategies.

Key Investor Takeaways

Rakovina increased AI-focused spending to 72% of its budget in Q2 2026 while cutting net loss 41% year over year.
The company closed the second and final tranche of its CA$1.99 million private placement after quarter-end, subject to final TSXV acceptance, to support ongoing programs.
Three AI-supported programs target ATR/mTOR, PARP/HDAC, and brain-penetrant PARP pathways with defined 2026-2027 milestones.
Preclinical data presented at AACR showed anti-tumor activity and CNS penetration for the kt-5000 series.
DNA damage response research remains an active area with interest from larger pharmaceutical companies.
Share structure shows modest market capitalization and insider ownership near 9.6%.¹

Rakovina Therapeutics' Q2 investor presentation outlines the full milestone schedule through the first half of 2027. [OWNERSHIP_CHART-11193]

Share Structure and Valuation Context¹

Edison Oncology holds approximately 9.9% of Rakovina Therapeutics. Management and reporting insiders account for about 9.64% ownership.

As of September 2, 2026, the company had approximately 44.32 million shares outstanding and a market capitalization of roughly CA$10.2 million. Shares traded in a 52-week range of CA$0.09 to CA$0.47.

Common Questions from Investors

What is Rakovina Therapeutics developing?

Rakovina Therapeutics is advancing three AI-supported programs that target DNA damage response pathways in cancer, combining computational screening with laboratory validation.

How much runway does the recent financing provide?

The CA$1.99 million private placement, subject to final TSX Venture Exchange acceptance, adds capital after the company reported CA$200,115 in cash at June 30, 2026.

What are the next milestones for the kt-5000AI program?

In vivo model data, lead optimization from an expanded AI collaboration, and lead selection are planned for 2026, with GLP toxicology studies targeted for the first half of 2027.

Which DDR pathways is Rakovina targeting?

The pipeline focuses on ATR/mTOR, PARP/HDAC, and PARP-selective inhibitors, areas that have drawn interest for selectivity and resistance management.

Where does Rakovina trade?

Rakovina Therapeutics trades on the TSX Venture Exchange under the ticker RKV.

Important Disclosures:

Rakovina Therapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rakovina Therapeutics Inc.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: RKV:TSX.V, )

Digital Health Platform Sees US Patient Visits Surge 196% and Quarterly YoY Revenue Jumps 43%

Thu, 03 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/03/2026

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported Q2 revenue of US$734,028 as U.S. patient visits nearly tripled and its in-network coverage expanded to approximately 24 million lives.

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported revenue of CA$734,028 for the second quarter ended June 30, 2026, up 43% from CA$512,756 in the same period of 2025. Revenue was broadly consistent with the CA$737,103 reported in the first quarter of 2026.

Completed U.S. patient visits increased 196% quarter over quarter to 3,911 from 1,319, while the company's active clinician network expanded from 19 to 30. Rocket Doctor said it currently has 80 providers on its roster, with the majority advancing through credentialing. In Canada, completed patient visits increased 23% year over year to 45,766 from 37,176.

"I am delighted to confirm the Company reported an organic 43% year-over-year increase in revenue for Q2 2026," Chief Executive Officer Dr. Essam Hamza stated in the company's news release. "This growth is supported by key 'in-network' payer agreements in the U.S., which have expanded our coverage to approximately 24 million covered lives across California, Maryland, and New York State."

Patient support fee revenue increased 5% from the first quarter, supported by platform utilization in Canada, while service revenue associated with the company's partnership with Rush River Research was slightly lower. The company said that revenue is expected to be recovered in the third and fourth quarters.

Rocket Doctor said certain U.S. revenues are currently recognized on a cash basis, resulting in a timing lag between patient visits and revenue recognition. The company said the full financial impact of the higher U.S. patient volume was therefore not reflected in second-quarter revenue and is expected to be recognized in future quarters.

Gross margin was 65%, compared with 75% in the first quarter of 2026 and 89% in the second quarter of 2025. The company attributed the decline to its revenue mix as it scaled its digital healthcare platform, particularly in the United States.

The company recorded a second-quarter net loss of CA$6.67 million, or CA$0.07 per share, compared with CA$4.64 million, or CA$0.05 per share, in the first quarter and CA$2.69 million, or CA$0.04 per share, a year earlier. Adjusted EBITDA was a loss of CA$4.12 million, compared with losses of CA$2.98 million in the preceding quarter and CA$1.73 million in the year-earlier period.

Cash and cash equivalents totaled CA$0.95 million as of June 30, 2026, compared with CA$0.64 million at Dec. 31, 2025.

During the quarter, Rocket Doctor expanded its U.S. insurance coverage, including agreements in Maryland and its first U.S. value-based primary care agreement. The company said its U.S. in-network footprint now covers approximately 24 million lives across California, New York, and Maryland.

Other developments included the launch of a Digital Health Observership Program with the University of Toronto for Physician Assistant students, a strategic marketing partnership with Rick Ware Racing and FINTEKK AP, and a partnership with Mindstride AI for after-hours and overflow physician coverage across Ontario, Alberta, and British Columbia. Treatment.com, the company's U.S. subsidiary, also secured US$250,000 in Year 2 NIH funding, bringing total support to more than US$500,000.

Since the end of the quarter, Rocket Doctor has announced SOC 2 Type 1 compliance, an extension of its EngageWell partnership in New York City, additional in-network access for more than 100,000 eligible members in New York, and a strategic network agreement in California. The company also closed two tranches of an oversubscribed convertible debenture financing totaling approximately CAD$3.26 million in gross proceeds.

Telehealth Sector Continues Expanding

J.P. Morgan Payments described telehealth in an August report as part of a broader shift toward digitalized healthcare, with virtual care increasingly combining remote medical services, connected devices, and digital payment infrastructure. The report cited research that valued the global telehealth market at US$83.5 billion in 2022 and estimated that US$250 billion of existing U.S. healthcare spending had the potential to be delivered virtually.

According to J.P. Morgan, digital healthcare channels had become increasingly important as patients sought more convenient ways to access care. Jeff Lin, co-leader of J.P. Morgan's Healthcare Payments business, said, "In competitive markets, like the U.S., health providers that fail to develop effective digital channels will lose out to those that do, especially amongst younger generations." The report also identified chronic disease management as a significant application for virtual care and connected medical devices. Lin said the industry's evolution increasingly combined multiple aspects of the healthcare experience: "So you're starting to see healthcare, telehealth, and payments all merging together at once."

An August 17 report from Fortune Business Insights valued the global telehealth market at US$186.41 billion in 2025 and estimated it at US$219.31 billion in 2026. North America accounted for 45.29% of the global market in 2025. The research firm described telehealth as "convenient, cost-effective, and expands access to healthcare services, especially in situations where in-person visits are not possible." It also said adoption had reached an all-time high in areas including radiology, cardiology, behavioral health, and online consultation, while remote patient monitoring had expanded.

Fortune Business Insights also identified virtual consultations as an important component of the sector. "Online video or audio consultations with medical professionals are becoming the norm," the firm wrote, citing cost effectiveness, shorter outpatient waiting times, and accessibility as factors behind greater use of electronic visits. The report said the services segment was expected to lead the market in 2026, supported by increased virtual consultations, startup financing, and teleconsultation reimbursement policies.

A separate Market U.S. telehealth market report published in August described virtual care as increasingly incorporated into routine healthcare delivery across primary care, chronic disease management, behavioral health, follow-up consultations, and specialty services. "Telehealth is being used across primary care, chronic disease management, behavioral health, follow-up consultations, and specialist services, helping reduce travel barriers and expand access for patients who may face challenges reaching traditional healthcare facilities," the report stated.

The report also noted that federal policy had extended several Medicare telehealth flexibilities through Dec. 31, 2027, including home-based telehealth for non-behavioral healthcare and the removal of certain geographic restrictions. Teleconsultation represented 41.2% of the U.S. telehealth market, while healthcare providers accounted for the largest end-user segment at 45.6%. Looking at the industry's broader role, the report said, "As digital health infrastructure, reimbursement policies, and provider capabilities continue developing, telehealth is positioned to remain an important component of the U.S. healthcare delivery system, particularly for improving convenience, accessibility, and continuity of care."

Analysts Maintain Bullish Outlook

¹Technical analyst Stewart Thomson highlighted Rocket Doctor AI's growing digital health platform on March 17, pointing to its potential to expand healthcare access, particularly in rural communities. Thomson noted that the platform was developed by physicians and argued that this gives Rocket Doctor an advantage in designing tools around clinicians' needs.

Thomson rated Rocket Doctor AI a "Strong Speculative Buy" and set a short-term technical price target of CA$0.80, a medium-term target of CA$1.00, and a long-term target of CA$1.60.

Fundamental Research Corp. analyst Sid Rajeev subsequently reiterated his "Buy" rating and CA$1.55 price target on June 11, 2026. While acknowledging that first-quarter results reflected higher costs and lower-than-expected patient volumes, Rajeev said he continued to see positive underlying trends.

"Supported by U.S. expansion, rising patient volumes, and sufficient liquidity, we expect meaningful operational and financial improvement over the coming quarters," Rajeev wrote.

What Could Drive Rocket Doctor's Next Stage of Growth

Rocket Doctor's August 2026 investor presentation pointed to U.S. expansion as one of the company's primary potential growth catalysts. The company reported approximately 24 million in-network patients through payer partners across California, New York, and Maryland, including 10.26 million in California, 9.98 million in New York, and 3.18 million in Maryland. Management identified Florida and Texas among the states in its expansion pipeline and said its strategy is to extend existing relationships with payers into additional markets.

Another catalyst could come from converting Rocket Doctor's physician pipeline into additional patient capacity. The presentation listed 81 physicians signed across California, New York, and Maryland, with 31 clinically active and 50 going through credentialing. Management estimated that completing this process could provide approximately three times the company's then-current physician capacity. The company said its credentialing infrastructure was developed over several years and is designed to support onboarding physicians into its U.S. payer network.

Further payer agreements represent another potential driver. Rocket Doctor's U.S. strategy targets Medicaid and Medicaid managed care, Medicare and Medicare Advantage, employer and commercial insurance plans, and out-of-network patients. Management said each additional payer relationship could provide access to 1 million to 2 million or more covered lives and create repeatable patient volume. The company also views out-of-network visits as a way to demonstrate demand to insurers and potentially convert those relationships into future payer contracts. [OWNERSHIP_CHART-10594]

Longer term, commercialization and broader integration of Rocket Doctor's AI technology could provide additional catalysts. Its Global Library of Medicine was developed with more than 25,000 hours of clinician input and approximately 10,000 expert medical reviews, according to the presentation, and is designed for integration into telehealth, health systems, medical education, pharmacy kiosks, nurse call centers, and voice assistants. Rocket Doctor is also developing AI-assisted intake, diagnostic support, referrals, documentation, and follow-up capabilities across its care platform.

Ownership & Share Information²

Rocket Doctor AI Inc. has a market cap of approximately CA$59.61 million, with 101.04 million shares outstanding. The company's 52-week range is CA$0.50-CA$0.98.

Management & Insiders own 4.24% of shares.

Frequently Asked Questions

What is Rocket Doctor AI?

Rocket Doctor AI Inc. (CSE: AIDR; OTC: AIRDF; FRA: 939) is a digital healthcare company focused on AI-powered healthcare infrastructure and virtual care delivery. Its platform combines digital health technology, payer access, and patient demand to help physicians and specialists provide care remotely. The company's technology includes its Global Library of Medicine, AI-assisted intake, diagnostic support, smart triage, AI scribe capabilities, and tools for patient follow-up.

How much did Rocket Doctor AI's revenue grow in Q2 2026?

Rocket Doctor reported Q2 2026 revenue of CA$734,028, an increase of 43% from CA$512,756 in Q2 2025. Revenue was broadly consistent with the CA$737,103 reported during Q1 2026.

How fast are Rocket Doctor AI's U.S. patient visits growing?

Completed U.S. patient visits increased 196% quarter over quarter in Q2 2026, reaching 3,911 compared with 1,319 in the previous quarter. The increase came as Rocket Doctor continued expanding its physician network and U.S. insurance coverage.

How many people are covered by Rocket Doctor AI's U.S. insurance network?

Rocket Doctor said its in-network payer relationships provided access to approximately 24 million covered lives across California, New York, and Maryland. Its August investor presentation listed approximately 10.26 million in-network patients in California, 9.98 million in New York, and 3.18 million in Maryland.

Where could Rocket Doctor AI expand its U.S. telehealth network next?

Rocket Doctor identified Florida and Texas among the states in its expansion pipeline. Management said its strategy included extending existing payer relationships, while its U.S. payer approach covered Medicaid and managed Medicaid, Medicare and Medicare Advantage, commercial insurance, and employer benefits.

How many doctors does Rocket Doctor AI have in its U.S. network?

Rocket Doctor reported 30 active U.S. clinicians during Q2 2026 and said it currently had 80 total providers on its roster, with the majority advancing through credentialing. Its August investor presentation separately listed 81 physicians signed across California, New York, and Maryland, including 31 clinically active physicians and 50 undergoing credentialing.

What is Rocket Doctor AI's Global Library of Medicine?

The Global Library of Medicine, or GLM, is part of Rocket Doctor AI's healthcare technology platform. According to the company, it was developed with more than 25,000 hours of input from hundreds of clinicians and approximately 10,000 expert medical reviews. The technology coversed more than 1,000 diseases and 17,000 symptoms and wasis designed to be integrated into 3rd party systems, as well as suggest appropriate laboratory tests, imaging, treatment options, and billing codes.

What are the potential growth catalysts for Rocket Doctor AI?

Potential catalysts identified in the company's August investor presentation included expanding payer coverage into additional U.S. states, credentialing additional physicians, increasing patient capacity, and further deploying its AI healthcare technology. Management said each additional payer could unlock access to 1 million to 2 million or more covered lives and create repeatable patient volume.

What is the outlook for the telehealth and digital healthcare market?

Fortune Business Insights valued the global telehealth market at US$186.41 billion in 2025 and estimated it would reach US$219.31 billion in 2026. North America represented 45.29% of the global market in 2025. The research firm identified virtual consultations, reimbursement policies, remote patient monitoring, and broader digital healthcare adoption among the factors shaping the telehealth industry.

What are analysts saying about Rocket Doctor AI stock?

Technical analyst Stewart Thomson rated Rocket Doctor AI a "Strong Speculative Buy" on March 17, with technical price targets of CA$0.80 in the short term, CA$1.00 in the medium term, and CA$1.60 over the long term. Fundamental Research Corp. analyst Sid Rajeev reiterated a "Buy" rating on June 11 with a CA$1.55 price target, citing U.S. expansion and rising patient volumes among the factors supporting his outlook.

Important Disclosures:

Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: AIDR:CSE; AIRDF:OTC; 939:FRA, )

AI Cancer Drug Pipeline Advances as 72% of Budget Shifts to Drug Discovery

Thu, 03 Sep 2026 00:00:00 PST

Source: Streetwise Reports 09/03/2026

Rakovina Therapeutics Inc. (RKV:TSX.V) cut its Q2 net loss 41% year over year while advancing three AI-powered cancer drug programs and closing a CA$1.99 million non-brokered private placement after quarter-end.

Rakovina Therapeutics Inc. (RKV:TSX.V) increased the share of its budget focused on AI-powered drug discovery to 72% in the second quarter of 2026, up from 57% in the same period of 2025, as the company continued advancing three AI-supported cancer drug programs.

The shift came as general and administrative expenses declined approximately 63% year over year to CA$450,695 from CA$1.21 million. Research and development expenses totaled CA$1.13 million during the quarter, while R&D spending for the first six months of 2026 reached CA$2.16 million, compared with CA$1.61 million in the same period of 2025. The company attributed the change to lower contract research and consulting costs, partially offset by increased chemistry and AI research activity.

"In Q2 2026, we reduced G&A by more than 60% year-over-year for a second consecutive quarter, such that 72% of our budget was focused on AI-powered drug discovery compared to 57% in Q2 2025," Chief Executive Officer Kim Oishi said in the company's news release. "Our focus for the balance of 2026 is advancing our three AI-powered drug discovery programs, enhancing relationships with our AI collaborators, and securing non-dilutive financing from industry and government sources."

Rakovina also reduced its quarterly net loss by approximately 41%, reporting a loss of CA$1.73 million for the three months ended June 30, compared with CA$2.92 million in the second quarter of 2025.

Following the end of the quarter, the company completed an upsized non-brokered private placement for aggregate gross proceeds of CA$1.99 million, subject to final acceptance by the TSX Venture Exchange. The first tranche closed August 12 for CA$1.39 million, after Rakovina increased the maximum offering from CA$1.5 million to CA$2 million.

As of June 30, Rakovina had CA$200,115 in cash and cash equivalents and a working capital deficit of CA$2.13 million, compared with CA$298,758 and a CA$2.15 million working capital deficit, respectively, at December 31, 2025.

The company also highlighted preclinical research presented at the American Association for Cancer Research Annual Meeting on April 22. Data from its kt-5000 series, a dual ATR-mTOR inhibitor program, demonstrated anti-tumor activity, selectivity, measurable central nervous system penetration, and tumor growth inhibition with improved tolerability relative to reference ATR inhibitors. Rakovina also presented initial formulation data for kt-3283, its dual PARP/HDAC inhibitor, demonstrating successful development of a lipid nanoparticle formulation.

At its August 19 annual general meeting, shareholders elected five directors and re-appointed Davidson & Company LLP as auditor. Dr. Petra Hamerlik joined the board, while Jeffrey Bacha retired as a director and continued in an advisory capacity.

AI Drug Programs Move Toward Lead Selection and Preclinical Studies

Rakovina Therapeutics' Q2 investor presentation laid out a series of 2026 and first-half 2027 milestones for its three AI-supported cancer drug programs. The presentation identified Rakovina as developing DNA Damage Response cancer therapies using AI platforms alongside laboratory validation at UBC and the Vancouver Prostate Centre.

Rakovina's kt-5000AI program is described as a dual ATR/mTOR inhibitor designed for CNS penetration and aimed at solid tumors, PTEN-deficient cancers, and CNS metastases. The presentation states that 138 molecules had been predicted and 43 synthesized, with leads confirmed as potent and selective. CNS penetration and tolerability had also been confirmed in vivo. Its stated 2026 milestones include in vivo model data at peer-reviewed meetings, lead-optimization results from an expanded AI collaboration, lead selection, and ongoing partner discussions.

The broader development schedule calls for kt-5000AI in vivo ADME and efficacy work and progress toward lead candidate selection during the third quarter of 2026. Lead selection is scheduled for the fourth quarter, followed by GLP toxicology and IND-enabling studies in the first half of 2027.

Rakovina's kt-3000 program targets PARP-resistant adult and childhood cancers, including Ewing sarcoma. The presentation states that the program's kt-3283 compound demonstrated superior cytotoxicity compared with FDA-approved olaparib and vorinostat, and was published in Clinical Cancer Research. Rakovina is working with NanoPalm on a proposed joint venture that would combine Rakovina's AI drug discovery capabilities with NanoPalm's self-targeting patterned lipid nanoparticle delivery system, with intellectual property arising from the collaboration to be jointly owned, while background IP and technology improvements remain with their respective inventors. The presentation lists 2026 milestones of securing joint venture funding, an ADC partnership, and nano-lipid formulation data at peer-reviewed meetings.

The development schedule calls for continued in vivo studies for the PARP/HDAC program during the third quarter of 2026 and GLP toxicology and IND-enabling studies during the first half of 2027. The presentation also describes further development of pLNP-kt-3283 through in vitro and in vivo characterization to confirm activity against PARP and HDAC enzymes, determine ADME properties, and determine efficacy against in vivo tumor models.

The third program, kt-2000AI, is a brain-penetrant PARP inhibitor targeting breast, ovarian, and prostate cancers. Rakovina said billions of compounds were screened through its Deep Docking platform, with 389 compounds assessed against PARP and leads confirmed with PARP selectivity and drug-like properties.

For kt-2000AI, the schedule calls for another round of AI output and advancing lead candidate selection in the fourth quarter of 2026, followed by PARP program lead selection in the first half of 2027. Corporate milestones in the presentation include finalizing a Saudi joint venture in the third quarter, seeking institutional funding, and attending the SNO, AACR-NCI-EORTC, and BIO Middle East conferences in the fourth quarter, followed by development of strategic pharmaceutical partnerships in the first half of 2027.

The broader biotechnology sector entered 2026 with a cautiously positive outlook despite continued financing and economic pressures. A June report from EY said biotech had recorded a third consecutive year of growth, with industry revenue increasing more than 12%, while financing reached US$68.5 billion in 2025, up 11% from the previous year. EY Americas Life Sciences Leader Arda Ural described the outlook as "rather positive," while the report identified AI-driven R&D as one of the areas positioned to contribute to continued innovation.

DNA Damage Response Research Expands Beyond First-Generation Inhibitors

A February 24 review published in Oncol Res described DNA damage response, or DDR, as a central factor in tumor survival, genomic stability, and therapy resistance. The authors wrote that "PARP inhibitors have established the DDR as a therapeutic target," while noting that some tumors had evaded first-generation drugs through adaptive repair pathways and constraints within the tumor microenvironment.

The review examined next-generation approaches involving PARP, ATR, ATM, CHK1, WEE1, and DNA-PK pathways, including inhibitors designed to increase selectivity and address resistance. It also examined nanocarrier-based delivery approaches intended to improve pharmacokinetics, target resistant tumor niches, and expand combinations with immunotherapy and radiotherapy. The authors concluded that the findings provided "a guide to the implementation of next-generation DDR inhibitors and nanomedicines to deliver a more accurate, durable, and context-specific cancer therapy."

According to a research topic published by Frontiers on August 16, DDR had served as "a critical cellular network that safeguards genomic stability by detecting and repairing DNA lesions." The publication described DDR's role in cancer as a "double-edged sword," because disruption of the system could contribute to genomic instability while adaptation of DDR mechanisms in cancer cells could contribute to resistance to DNA-damaging therapies.

Frontiers also identified therapeutic vulnerabilities created by defects in particular DDR pathways. It said targeted approaches, including PARP inhibitors, had "successfully exploited this weakness," while inhibitors targeting DDR-related proteins, including ATM, ATR, CHK1, CHK2, and WEE1, had emerged as areas of continued research. The research topic focused on DDR mechanisms in tumorigenesis, resistance to DDR-targeted therapies, development and optimization of small-molecule inhibitors, and DDR-associated biomarkers for cancer detection and personalized treatment. [OWNERSHIP_CHART-11193]

In August 2026 materials, AstraZeneca described DNA Damage Response as one of the scientific mechanisms being studied to advance more targeted approaches in oncology. The company said most cancers had a greater dependency on DDR because they had lost one or more DNA repair capabilities during cancer development, creating opportunities to identify those dependencies and use precision medicine approaches and targeted DDR inhibitors.

"By understanding and identifying these dependencies, we can use precision medicine approaches and targeted DDR inhibitors to maximize DNA damage and selectively kill cancer cells," AstraZeneca wrote. The company also said DDR research had contributed to biomarker-selected treatment strategies across ovarian, breast, prostate, and pancreatic cancers, while ongoing work included identifying genetic biomarkers associated with DDR defects and studying DDR inhibitor combinations with other targeted therapies to address resistance and support more durable responses.

Ownership and Share Structure¹

Edison Oncology holds approximately 9.9% of Rakovina Therapeutics. Management and reporting insiders account for about 9.64% ownership, with the remainder held by a combination of institutional, retail, and other investors, as previously disclosed in company materials.

As of September 2, 2026, Rakovina Therapeutics had approximately 44.32 million issued and outstanding shares, and the company's market capitalization was approximately CA$10.2 million. Rakovina's shares had traded within a 52-week range of approximately CA$0.09 to CA$0.47 per share.

Frequently Asked Questions

What is Rakovina Therapeutics, and what does the company do?

Rakovina Therapeutics Inc. is a biotechnology company developing DNA Damage Response cancer therapies. Its drug discovery work combines artificial intelligence platforms with laboratory validation as it advances multiple oncology drug programs.

How is Rakovina Therapeutics using AI for cancer drug discovery?

Rakovina Therapeutics uses AI-supported drug discovery platforms to evaluate large numbers of compounds and identify potential cancer drug candidates. Its pipeline includes programs using generative AI and Deep Docking technology, followed by laboratory testing and preclinical validation.

What are DNA Damage Response inhibitors in cancer treatment?

DNA Damage Response, or DDR, encompasses cellular pathways involved in detecting and repairing damaged DNA. DDR has become a therapeutic target in oncology, with researchers studying inhibitors targeting pathways and proteins including PARP, ATR, ATM, CHK1, WEE1, and DNA-PK.

What cancer drug candidates are in the Rakovina Therapeutics pipeline?

Rakovina's pipeline includes three primary programs: kt-5000AI, a dual ATR/mTOR inhibitor designed for CNS penetration; kt-3000, a dual PARP/HDAC inhibitor targeting PARP-resistant adult and childhood cancers; and kt-2000AI, a brain-penetrant PARP inhibitor being developed for breast, ovarian, and prostate cancers.

What is Rakovina Therapeutics' kt-5000AI drug program?

Kt-5000AI is a dual ATR/mTOR inhibitor designed for CNS penetration and targeting solid tumors, PTEN-deficient cancers, and CNS metastases. According to the company's Q2 2026 investor presentation, 138 molecules had been predicted and 43 synthesized, with leads confirmed as potent and selective. The company also reported that CNS penetration and tolerability had been confirmed in vivo.

What are Rakovina Therapeutics' upcoming drug development milestones?

The company's development schedule included in vivo ADME and efficacy work and progress toward kt-5000AI lead candidate selection in Q3 2026, followed by lead selection in Q4. For kt-2000AI, another round of AI output and advancement of lead candidate selection were scheduled for Q4 2026. The first half of 2027 included planned GLP toxicology and IND-enabling studies for the ATR/mTOR and PARP/HDAC programs and lead selection for the PARP program.

Why are ATR and PARP inhibitors being researched for cancer treatment?

ATR and PARP are among the components of DNA Damage Response pathways being investigated as therapeutic targets in oncology. Research has examined how vulnerabilities created by defects in cancer cells' DNA repair mechanisms can be targeted, while next-generation DDR research has also focused on selectivity, drug resistance, and combination treatment strategies.

What role does brain penetration play in Rakovina Therapeutics' cancer research?

Two of Rakovina's programs specifically address CNS penetration. Kt-5000AI is described as a dual ATR/mTOR inhibitor designed to reach the brain, while kt-2000AI is being developed as a brain-penetrant PARP-selective inhibitor.

What is Rakovina Therapeutics doing with its PARP/HDAC inhibitor program?

The kt-3000 program targets PARP-resistant adult and childhood cancers, including Ewing sarcoma. The company's presentation described work involving the kt-3283 compound and a patterned lipid nanoparticle formulation, with additional in vitro and in vivo characterization planned to evaluate activity, ADME properties, and efficacy in tumor models.

What is the current focus of DNA Damage Response cancer research?

Current DDR research has extended beyond established PARP inhibitors to include targets such as ATR, ATM, CHK1, CHK2, WEE1, and DNA-PK. Research has also examined resistance mechanisms, biomarkers, combination therapies, next-generation inhibitors, and drug-delivery approaches intended to target resistant tumor environments.

How does precision medicine relate to DNA Damage Response therapies?

DDR research has examined genetic and molecular characteristics that can identify vulnerabilities in cancer cells. Biomarkers associated with DDR defects can help researchers investigate patient selection and targeted treatment strategies, making DDR an area of research within precision oncology.

What is the Rakovina Therapeutics stock symbol?

Rakovina Therapeutics trades on the TSX Venture Exchange under the ticker RKV and in Frankfurt under the ticker 7JO0.

Important Disclosures:

Rakovina Therapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rakovina Therapeutics Inc.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: RKV:TSX.V, )

REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances

Mon, 31 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/31/2026

REGENXBIO's RGX-121 gene therapy faces an FDA clinical hold after spinal MRI findings, while the Duchenne muscular dystrophy program remains on track for its Q3 2026 BLA submission, along with wet AMD pivotal data expected in Q4.

REGENXBIO Inc. (RGNX:NASDAQ) announced on August 24, 2026, that the FDA placed a clinical hold on its RGX-121 gene therapy candidate after asymptomatic spinal MRI findings appeared in five participants of the CAMPSIITE study. The company is now working with partner NS Pharma to review longer-term imaging and follow-up data to determine clinical significance.

REGENXBIO stated it believes the findings are unique and limited to its Hunter Syndrome program, while its Duchenne and retinal disease candidates use different capsids and routes of administration.

Why the Clinical Hold Matters for Retail Investors Right Now

A clinical hold pauses further dosing in a study while regulators evaluate safety data. For investors, the immediate question is whether this action delays the broader pipeline or remains isolated.

REGENXBIO emphasized that its Duchenne muscular dystrophy and retinal disease programs continue without interruption.

Key Investor Takeaways

RGX-121 for Hunter Syndrome (MPS II) is on clinical hold after asymptomatic MRI findings in five patients, with further data review underway.
REGENXBIO plans to submit a BLA for RGX-202 in Duchenne muscular dystrophy during Q3 2026, unchanged by the hold.
Topline pivotal data for Surabgene Lomparvovec (Sura-Vec, ABBV-RGX-314) in wet AMD is still expected in Q4 2026.
The Hunter Syndrome treatment market is projected to reach US$1.8 billion by 2030, growing at a 5.3% CAGR.
REGENXBIO holds Orphan Drug, Fast Track, and RMAT designations for RGX-121, though a near-term BLA resubmission is not expected.

Company Advantages in One-Time Gene Therapies

REGENXBIO develops single-administration gene therapies for rare diseases and retinal conditions. The company uses adeno-associated virus vectors to deliver functional genes, aiming to provide durable therapeutic effects after one treatment.

This approach differs from chronic enzyme replacement therapies that require repeated dosing.

Key Assets and Next Catalysts

The company investor presentation outlines two major near-term milestones. A BLA submission for RGX-202 in Duchenne muscular dystrophy is scheduled for Q3 2026, with potential ex-US randomized controlled trial initiation in the first half of 2027.

Topline pivotal data for the wet AMD candidate Surabgene Lomparvovec is targeted for Q4 2026, followed by global regulatory submissions in 2027.

Broader Rare Disease Market Timing

According to Grandview Research, the global Hunter Syndrome treatment market was valued at US$1.3 billion in 2024 and is projected to grow from US$1.5 billion in 2026 to US$1.8 billion by 2030 at a 5.3% CAGR. North America accounted for 37.5% of revenue in 2024, driven by greater disease awareness and treatment availability.

IQVIA discussed the global pharma market projection for 2026, noting that innovative therapeutics in oncology, immunology, and rare diseases will drive spending growth through 2030.

Views and Valuation Context

Chen Lin of What is Chen Buying? What is Chen Selling? noted the stock traded below the last financing price of US$9 and added shares, stating the clinical hold is unlikely to affect the Duchenne program.

Marketbeat lists the following recent ratings:

Yi Chen of H.C. Wainwright reiterated Buy with a price target lowered from US$23 to US$21.
Brian Skorney of Robert W. Baird reiterated an Outperform rating with a target lowered from US$32 to US$29.
Gena Wang of Barclays downgraded from Overweight to Hold.

Share Structure and Near-Term Events¹

REGENXBIO Inc. has a market cap of US$618.54 million and 66.01 million shares outstanding. The 52-week range is US$5.46-US$16.19. [OWNERSHIP_CHART-11689]

Institutions hold 65.40% of shares, Strategic Investors hold 0.41%, Management & Insiders hold 5.97%, and Retail investors hold the remaining 28.22%.

Common Questions from Investors

Q: What triggered the FDA clinical hold on RGX-121?
A: Asymptomatic spinal MRI findings were observed in five participants in the CAMPSIITE study for Hunter Syndrome.

Q: Will the hold affect the Duchenne muscular dystrophy program?
A: REGENXBIO believes the findings are unique and limited to its Hunter Syndrome program. The company said its Duchenne and retinal disease candidates use different capsids and routes of administration, and its planned Duchenne BLA submission remains on track for Q3 2026.

Q: When is the next major catalyst for REGENXBIO?
A: The company plans to initiate a BLA submission for RGX-202 in Q3 2026, with wet AMD pivotal data expected in Q4 2026.

Q: What is the size of the Hunter Syndrome treatment market?
A: The market is projected to grow from US$1.5 billion in 2026 to US$1.8 billion by 2030 at a 5.3% CAGR.

Investors should monitor upcoming FDA correspondence and data reviews for RGX-121 while tracking the scheduled BLA submission and pivotal readout timelines for the unaffected programs.

Important Disclosures:

Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: RGNX:NASDAQ, )

REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy

Fri, 28 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/28/2026

REGENXBIO Inc. (RGNX:NASDAQ) faces an FDA clinical hold on RGX-121 after spinal MRI findings in five patients, while its Duchenne and wet AMD programs remain on track.

Key Takeaways

REGENXBIO's RGX-121 gene therapy faces an FDA clinical hold after asymptomatic spinal MRI findings were identified in five participants in the CAMPSIITE study.
The company is evaluating additional imaging and long-term follow-up data with partner NS Pharma to determine the findings' clinical significance and next steps for RGX-121.
REGENXBIO's other late-stage programs remain on track, including a planned BLA submission for its Duchenne muscular dystrophy gene therapy candidate RGX-202 and fourth-quarter 2026 pivotal data for surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD.
The Hunter Syndrome treatment market is projected to grow, while REGENXBIO continues to develop one-time gene therapies for rare and retinal diseases.

Hunter Syndrome Program Under Further Review

On August 24, 2026, REGENXBIO Inc. (RGNX:NASDAQ) gave an update on RGX-121 (clemidsogene lanparvovec), its investigational gene therapy intended to treat Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. Hunter Syndrome is a rare, X-linked recessive disease that is caused by a deficiency in the lysosomal enzyme I2S that leads to an accumulation of glycosaminoglycans (GAGs), including heparan sulfate (HS), in tissues. This accumulation results in cell, tissue, and organ dysfunction. Hunter Syndrome is diagnosed in around 2,000 patients globally, with over 500 babies born with the disease every year. According to the press release, the majority of MPS II patients have severe forms of the disease, with early developmental milestones potentially being met but developmental delays becoming readily apparent by 18 to 24 months.

In the announcement, REGENXBIO stated that the FDA (The U.S. Food and Drug Administration) has placed a clinical hold on RGX-121 after the discovery of asymptomatic spinal MRI findings in five participants in its CAMPSIITE study.

"We believe these findings are unique and limited to our Hunter Syndrome program, and require longer-term follow-up and additional data analysis to assess the benefit-risk profile of RGX-121," said Curran Simpson, President and CEO of REGENXBIO. "We remain focused on our Duchenne and retinal disease candidates, which utilize a different capsid and routes of administration, with near-term catalysts that are on track, including the planned submission of the Duchenne BLA this quarter and the wet AMD topline pivotal data announcement in the fourth quarter."

Because spine MRI is not normally conducted for MPS II in clinical practice or trials, the underlying prevalence and clinical significance of these types of asymptomatic findings in this patient population is unknown. Investigators plan to continue observing these patients with periodic imaging only.

"Boys with neuronopathic MPS II experience a multitude of neurodevelopmental and systemic effects. While imaging natural history is limited for this ultra-rare disease, I believe that asymptomatic, likely benign findings like these may be inherent to the impact of Hunter Syndrome throughout the body," said Roberto Giugliani, MD, Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil. "I am pleased that these patients are doing well and remain asymptomatic."

The company and its partner, NS Pharma, are evaluating additional patient imaging and longer-term follow-up data. FDA feedback will be incorporated, including the full clinical hold letter once received, into the next steps for RGX-121.

REGENXBIO does not expect to resubmit the RGX-121 Biologics License Application (BLA) in the near term, even though it has received Orphan Drug Product, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations from the U.S. Food and Drug Administration, and advanced therapy medicinal products (ATMP) classification from the European Medicines Agency.

A biopharma company, REGENXBIO, is focused on advancing a late-stage pipeline of one-time treatments for rare and retinal diseases using gene therapy.

Rare Disease Market Continues to Grow

According to Grandview Research, "The global hunter syndrome treatment market size was valued at US$1.3 billion in 2024 and is projected to grow from US$1.5 billion in 2026 to USD 1.8 billion by 2030, at a CAGR of 5.3% from 2025 to 2030." In 2024, the North American market showed the most demand, with a revenue share of 37.5%, due to increasing awareness of the disease and more readily available treatments.

In February 2026, IQVIA discussed the global pharma market projection for 2026, projecting that global medicine usage will approach four trillion defined daily doses by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Biopharma funding fell 20% between 2024 and 2025, according to an IQVIA analysis reported in a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Views and Valuations

On August 25, 2026, Chen Lin of What is Chen Buying? What is Chen Selling? wrote about the company, saying: "Biotech is full of surprises and a big movement. RGNX was down big this week due to one of the other pipeline drug candidates [being] put on clinical hold. Unlikely it has any impact on their key catalysts, which is the DMD program that is pending FDA approval. I had discussions with other hedge funds who follow this closely, [and] the worst case is the FDA delaying the current approval by a few months out of extraordinary precautions. The shares are down below the last financing price of US$9; I added a few shares to lower my cost."

As for analyst coverage, Marketbeat lists recent analyst ratings as:

On August 25, 2026, Yi Chen of H.C. Wainwright reiterated a "Buy" rating but lowered the price target from US$23 to US$21.
On August 25, 2026, Brian Skorney of Robert W. Baird reiterated a "Buy" rating but lowered the price target from US$32 to US$29.
On August 7, 2026, Gena Wang of Barclays downgraded the rating from "Overweight" to "Hold".

Duchenne and Wet AMD Programs Offer Near-Term Catalysts

REGENXBIO's investor presentation lists upcoming catalysts for several investigational drugs, including:

The initiation of a BLA submission for RGX-202, its Duchenne muscular dystrophy gene therapy candidate, in Q3 2026. The company hopes to initiate ex-US RCT in the first half of 2027 and looks forward to potential FDA approval in the second half of 2027.
The receipt of topline pivotal data for its wet AMD gene therapy candidate, surabgene lomparvovec (sura-vec, ABBV-RGX-314), in Q4 2026 and global regulatory submissions planned for 2027.

Ownership & Share Information¹

REGENXBIO Inc. has a market cap of US$618.54 million, with 66.01 million shares outstanding. The company's 52-week range is US$5.46-US$16.19. Institutions own 65.40% of shares, while Strategic Investors own 0.41%. Management & Insiders own 5.97%, and the remaining 28.22% of shares are held by Retail.[OWNERSHIP_CHART-11689]

Frequently Asked Questions

Q: What is Hunter Syndrome?
A: Hunter Syndrome, also known as MPS II, is a rare inherited disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S). The deficiency causes certain complex sugars to accumulate in tissues and organs.

Q: What is RGX-121?
A: RGX-121, also known as clemidsogene lanparvovec, is an investigational gene therapy being developed by REGENXBIO to treat Hunter Syndrome.

Q: What is a clinical hold?
A: A clinical hold is an FDA action that pauses some or all clinical investigation of an experimental drug while safety or other regulatory concerns are evaluated.

Q: What is a BLA?
A: A Biologics License Application, or BLA, is a submission to the FDA requesting approval to market a biological product, including certain gene therapies.

Q: What is gene therapy?
A: Gene therapy is an approach that seeks to treat or potentially prevent disease by modifying, replacing, adding, or regulating genetic material within a patient's cells.

Q: What is an orphan drug designation?
A: The FDA's Orphan Drug Designation is intended for drugs developed to treat rare diseases or conditions. The designation can provide certain development incentives and potential regulatory benefits.

Q: What is MPS II?
A: MPS II, or mucopolysaccharidosis type II, is the medical name for Hunter Syndrome. It is an X-linked genetic disorder that can cause progressive effects across multiple organs and tissues.

Q: What are glycosaminoglycans?
A: Glycosaminoglycans, or GAGs, are complex sugar molecules found throughout the body. In Hunter Syndrome, the body cannot properly break down certain GAGs, causing them to accumulate.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: RGNX:NASDAQ, )

Coya Therapeutics Advances Phase 2 ALSTARS ALS Trial Toward 2026 Enrollment Finish

Tue, 25 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/25/2026

Coya Therapeutics moves COYA 302 through Phase 2 ALSTARS for ALS with enrollment completion expected in 2026 and topline data in Q1 2027. Learn key catalysts, pipeline details, and analyst targets.

Houston-based Coya Therapeutics Inc. (COYA:NASDAQ) is advancing its lead candidate through a Phase 2 study in amyotrophic lateral sclerosis. The company expects to finish enrollment in the ALSTARS trial during 2026 and deliver topline results in the first quarter of 2027.

This timeline represents the nearest major catalyst for investors tracking Coya. Positive data could support later-stage development and help clarify the therapy's potential in a disease area with few approved options.

Why the ALSTARS Timeline Matters for Investors Now

ALS is a progressive neurodegenerative condition where neuroinflammation contributes to worsening symptoms over time. Current treatments offer limited benefit, so any therapy that meaningfully slows functional decline would address a clear unmet need. Coya's trial design focuses on a 24-week period and uses the ALSFRS-R scale to measure change, providing a direct read on whether the drug slows disease progression.

The company has already moved the first cohort into a blinded extension phase, keeping the study on schedule. Cash and cash equivalents of US$43.2 million as of June 30, 2026, are expected to fund operations past the ALSTARS topline readout and into H2 2027.

Coya's Distinct Treg-Focused Approach

Coya develops therapies that aim to restore the anti-inflammatory and immune-regulating functions of regulatory T cells. Its pipeline includes several Treg-focused approaches, with COYA 302 combining low-dose interleukin-2 and CTLA-4 Ig. The goal is to increase Treg numbers and function while also limiting inflammatory immune activity.

This dual mechanism is being tested first in ALS but is also under consideration for other neurodegenerative conditions. The FDA has granted Fast Track designation for the ALS program, which can expedite regulatory interactions if data are supportive.

Key Assets, Next Catalysts, and Pipeline Expansion

Beyond the ALSTARS ALS study, Coya is preparing a Phase 2a trial of COYA 302 in frontotemporal dementia after the FDA accepted the investigational new drug application in January 2026. Additional data readouts expected in the second half of 2026 include biomarker results from frontotemporal dementia work, single-cell proteomics from ALS and Alzheimer's studies, and animal-model findings for COYA 303.

The company also holds proof-of-concept data from an academic study of COYA 301 in Alzheimer's disease, illustrating broader platform potential across neurodegenerative and autoimmune settings.

Analyst Views and Valuation Context

Four analysts maintain Buy ratings with an average price target of US$15.63.

Raghuram Selvaraju of H.C. Wainwright reiterated a Buy rating and US$18 target, noting that positive ALSTARS data could support pivotal trials in late 2027.

Boobalan Pachaiyappan of Roth Capital Partners reiterated a Buy and US$12 target, highlighting the need for a clinically meaningful ALSFRS-R improvement relative to placebo.

Ilya Zubkov of Freedom Broker reiterated a Buy and US$15.50 target, pointing to the cash runway past the first-quarter 2027 readout.

Chad Messer of Lake Street Capital Markets reiterated a Buy and US$17 target based on modeled U.S. ALS sales and royalty economics.

Key risks cited across the notes include clinical or regulatory setbacks for COYA 302, delays reaching later-stage trials, commercial uptake challenges, and potential future equity dilution.

Share Structure and Near-Term Events²

Coya has a market capitalization of US$114.24 million based on 23.46 million shares outstanding. The 52-week trading range is US$3.71 to US$7.75. Insiders hold 1 percent, strategic investors hold 13.69 percent, institutions hold 33.23 percent, and retail investors hold the remaining 52.08 percent. [OWNERSHIP_CHART-11262]

Key Investor Takeaways

ALSTARS Phase 2 enrollment completion expected in 2026, with topline data targeted for Q1 2027.
COYA 302 combines low-dose IL-2 and CTLA-4 Ig to modulate Tregs and inflammation in ALS.
Cash position of US$43.2 million from operations into H2 2027, past the primary readout.
Frontotemporal dementia Phase 2a study planned after IND acceptance in January 2026.
Average analyst target of US$15.63 with four Buy ratings; risks include clinical failure and dilution.¹
Market cap of US$114.24 million on 23.46 million shares with a 52-week range of US$3.71-US$7.75.

Common Questions from Investors

What is the primary near-term catalyst for Coya? Completion of ALSTARS enrollment in 2026 and topline results in the first quarter of 2027.

Does Coya have cash to reach the readout? Management states that Coya had US$43.2 million in cash and cash equivalents as of June 30, 2026, sufficient to fund operations past the ALSTARS topline readout and into the second half of 2027.

Is COYA 302 approved? No, it remains investigational and has not received FDA approval.

What other indications are planned? A Phase 2a study in frontotemporal dementia is scheduled to begin in the coming months.

Where can investors find the latest corporate update? Coya said in its August 2026 corporate update that enrollment is proceeding as planned.

Retail investors evaluating Coya should weigh the upcoming clinical milestones against the inherent risks of early-stage biopharmaceutical development, including the possibility that COYA 302 may not demonstrate sufficient efficacy or safety to advance further.

Important Disclosures:

Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Street Smart Average Price Target Formula

Street Smart Consulting has attained an average price target and rating for this company from our system's formula. The system calculates an average of all analyst target prices, which are originally in Canadian or U.S. dollars, then converts them to both dollar amounts. For the recommendation, it selects whichever rating (Buy, Sell, Hold, etc.) appears most frequently among analysts. When there's a tie for the most common recommendation, all tied ratings are included.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Disclosures for H.C. Wainwright & Co., Coya Therapeutics, August 24:

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet. H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

I, Raghuram Selvaraju, Ph.D., MBA, MS, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Coya Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of July 31, 2026 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Coya Therapeutics, Inc.. Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. H.C. WAINWRIGHT & CO. EQUITY RESEARCH 3 This report is intended for ssobek@streetwisereports.com. Unauthorized distribution prohibited. Coya Therapeutics, Inc. August 24, 2026 The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from Coya Therapeutics, Inc. for non-investment banking services in the previous 12 months. The Firm or its affiliates did receive compensation from Coya Therapeutics, Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Coya Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

Disclosures for Roth Capital Partners, Coya Therapeutics, August 23, 2026:

Shares of Coya Therapeutics, Inc. may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities. ROTH Capital Partners, LLC and its affiliates expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH. Copyright 2026. Member: FINRA/SIPC.

Disclosures for Freedom Broker, Coya Therapeutics, August 17, 2026:

Freedom Broker’s Analyst Rating Calculation Disclosure The Analyst Rating (“AR”) is calculated as follows: Analyst Rating (AR) = Expected Price Return / Annualized Historical Volatility 1. Expected Price Return Expected Price Return is calculated using the following formula: Expected Price Return = (Price Target / Current Price) − 1 This figure represents the percentage price appreciation or decline implied by the analyst’s 12-month price target relative to the stock’s current market price. 2. Annualized Historical Volatility Annualized Historical Volatility is calculated as follows: Annualized Historical Volatility = Standard Deviation of Daily Logarithmic Returns × √252 For securities with at least 12 months of trading history, the calculation uses daily logarithmic returns over the preceding 12 months. If fewer than 12 months of trading history are available, the calculation uses all available daily price history. Volatility calculated using a shorter trading history may be less representative of the security’s longer-term trading behavior. Daily logarithmic returns are calculated as the natural logarithm of the ratio of the current trading day’s closing price to the preceding trading day’s closing price: Daily Logarithmic Return = ln(Current Closing Price / Previous Closing Price) The standard deviation of daily logarithmic returns is annualized by multiplying it by the square root of 252, representing the approximate number of trading days in a year. Once calculated, the AR expresses the expected price return implied by the analyst’s price target as a proportion of the stock’s historical annualized volatility. The AR does not represent the probability that the stock will reach its price target. Historical volatility, particularly when calculated using a shorter trading history, may not be indicative of future volatility. Ratings reflect the information and market conditions available as of the date of the relevant research report and are not automatically changed solely as a result of subsequent movements in the stock’s market price. Investors should carefully review the entire Report, including the definitions of all ratings, and should not base investment decisions solely on a stock’s stated rating. DISTRIBUTION OF INVESTMENT RATINGS The following shows (1) the distribution of investment ratings for all FREEDOM coverage universe stocks and (2) the proportions of stocks of each rating to which FREEDOM has provided investment banking (IB) services within the past 12 months (updated as of Aug 17 2026).

This Report contains forward-looking statements, which involve risks and uncertainties. FREEDOM has not independently verified the facts, assumptions and estimates contained in this Report. SOME ANALYSTS MAY NOT HAVE OFFICIAL RATINGS. The Firm and any affiliates may offer an informal view as to the direction of a price trend in a group of stocks, industry, index, derivative or commodity and such view or description should never be interpreted or construed as any type of formal equity recommendation. It is possible that this informal view conflicts with the views of FREEDOM’s trading desk and that of FREEDOM. Any view that we offer in the possible direction of any instrument cannot and should never be relied upon as any type of recommendation. The views in this Report should not be used as a basis for buying or selling any stock, group of stocks, industry, index, derivative or commodity. FREEDOM and its affiliates cannot be held liable for any actions, interpretations or consequence that might result in a loss. Any loss or other consequence arising from the use of this Report shall be your sole and exclusive responsibility and FREEDOM does not accept liability for any such loss or consequence. Other Important Disclosures Our research is disseminated primarily electronically and, in some cases, in printed form. Electronic research is simultaneously available to all clients. Individual consultations with our analysts may not be disseminated electronically by the Firm. All material presented in this Report, unless specifically indicated otherwise, is under copyright of FREEDOM. No part of this material may be (i) copied, photocopied or duplicated in any form by any means, or (ii) redistributed without prior written consent of FREEDOM. Important Disclosures on Subject Companies FREEDOM expects to receive or intends to seek compensation for investment banking services from the following subject company(ies) within the next 3 months: Coya Therapeutics, Inc. This Research Report (“Report”) was prepared by Freedom Finance Global PLC (ffin.global) (“Freedom Broker”), which provides brokerage (agency) services in the securities market in the territory of the Astana International Financial Centre (AIFC) in the Republic of Kazakhstan under License No. AFSA-A-LA-2020-0019 issued by the Astana Financial Services Authority. Freedom Broker is an affiliate of Prime Executions, Inc. (“Prime Executions”), A Member New York Stock Exchange, FINRA, & SIPC, and a wholly owned subsidiary of Freedom Holding Corp. (NASDAQ: FRHC). Prime Executions accepts responsibility for the content of Reports prepared by Freedom Broker when made available to U.S. persons other than Major U.S. Institutional Investors. This Report is not a solicitation by Freedom Broker. Specifically, Freedom Broker does not do business with any individuals or entities that are domiciled in, or citizens of, the United States. Individuals or entities domiciled in, or citizens of, the United States that wish to effect transactions in securities discussed in this Report must do so through Prime Executions. Freedom Finance Global PLC (ffin.global) (“Freedom Broker”) prepared this Report. The analysts who contributed to this Report, Boris Tolkachev, PhD and Ilya Zubkov, are employed by Freedom Broker, are not registered as Research Analysts with the Financial Industry Regulatory Authority (“FINRA”), may not be associated persons of Freedom Capital Markets, and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. Investment Research Disclaimer This Report is investment research. The Report is confidential and is solely for the use of those whom a member of FREEDOM directly distributes it. Neither the whole Report nor any part of it may be: reproduced to third parties; disclosed to, or used or relied upon by, any other person or used for any other purpose. Neither the information contained in the Report or on which such Report is based (together, the “Information”) nor the opinions expressed herein constitutes, or is to be construed as, an offer or invitation or other solicitation or recommendation to buy or sell investments. The Information is based on various sources which we believe to be reliable. However, such Information has not been independently verified by FREEDOM and accordingly, neither FREEDOM nor its affiliates make any representation or warranty, express or implied, with respect to the accuracy or completeness of Production completed: August 17, 2026 (14:32 EDT) Report disseminated: August 17, 2026 (14:32 EDT) 7 Company Update Coya Therapeutics, Inc. (COYA) the Information or that the Information remains unchanged after the issue of this Report (including, without limitation, that the research on the subject company is withdrawn). No reliance may be placed for any purpose whatsoever on the Information, representations, estimates or opinions. Any projections, opinions, forecasts or estimates in this Report are those of the author only; they reflect only current views of the author and are subject to change without notice. Salespeople and traders of FREEDOM and other professionals may provide oral or written market commentary or trading strategies to our clients and our proprietary trading desks that reflect opinions that are contrary to the opinions expressed in this Report. The investments discussed in this Report (together, the “Investments”; each an “Investment”) are not suitable for all investors and this Report does not take into account the recipients’ suitability requirements or investment risk appetite. You should make your own investment decisions based upon your own financial objectives and financial resources and it should be noted that investment involves risk. You should consider this Report as only a single factor in making your investment decision. Any decision to purchase any Investment must take into account existing public information on the relevant Investment or any registered prospectus. Please note that past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. Where an investment is made in currencies other than the currency of the Investments, movements in exchange rates will have an effect on the value, either favorable or unfavorable. In the event of any doubt about any investment, you should contact your own investment, legal, and/or tax advisers to seek advice regarding the appropriateness of investing. Any loss or other consequence arising from the use of this Report shall be your sole and exclusive responsibility and FREEDOM does not accept liability for any such loss or consequence. In the event this Report is sent to you by a party other than FREEDOM, please note that the contents may have been altered from the original, or comments may have been added, which may not be the opinions or views of FREEDOM. In such case, FREEDOM is not responsible for this amended Report. Certain affiliates of Prime Executions may have a long or short position in any securities of the issuer or in related investments. The analysis and recommendations contained herein are the opinion of the research analysts writing the Report (or the research department) and may not be reflective of the opinion of FREEDOM or any of its associated non-research personnel. Freedom Capital Markets is the investment banking and equity capital markets arm of Prime Executions, Inc., a Member New York Stock Exchange, FINRA, & SIPC, and a wholly owned subsidiary of Freedom Holding Corp. (NASDAQ: FRHC). For the Investments in which FREEDOM is a market maker, FREEDOM may provide bids and offers and may act as principal or in a riskless principal capacity in connection with such transactions. FREEDOM may act as agent in the traded financial instruments linked to Investment that may have been recommended in this Report; it may, at any time, hold a trading position (long or short) in the shares of the companies discussed in this Report and may engage in Investments in a manner inconsistent with this Report and, with respect to Investment, may buy or sell from customers on a riskless principal or agency basis.

Country-specific Disclaimers Kazakhstan Freedom Finance Global PLC ("Freedom Broker") (hereinafter referred to as the "Company") provides brokerage (agency) services in securities market of the Astana International Financial Centre (AIFC) in the Republic of Kazakhstan. In accordance with requirements, conditions, restrictions, and/or guidelines of applicable AIFC legislation, the Company is authorized to carry out the following regulated activities under License No. AFSA-A-LA-2020-0019: investment transactions as a principal, investment transactions as an agent, investment management, management of a collective investment scheme, providing investment consulting and arranging transactions in investments. This section contains information and materials, which are provided to the Company’s clients for informational and reference purposes only. These materials and information do not constitute individual investment advice, an offer or an invitation to invest in shares of any companies. The materials presented in this document have purely informational nature concerning the subject of investment research (hereinafter referred to as the "Issuer") and are addressed to the Company’s current and potential retail clients. The information contained in this document has been obtained from public open sources and is deemed reliable by the author(s). However, the author(s) makes no guarantees or warranties, obvious or implied, regarding to its accuracy or completeness. This document shall not be considered as a basis for making investment decisions by individuals or legal entities. These materials do not constitute investment advice, nor are they an offer or a call to buy or sell securities. Ownership of securities and other financial instruments always involves risks: the value of securities and other financial instruments may rise or fall. Past investments do not guarantee future incomes. In accordance with applicable legislation, the Company neither guarantees nor promises future investment returns and does not provide assurances regarding the reliability of potential investments or the stability of prospective income levels. Disclosure of Information Production completed: August 17, 2026 (14:32 EDT) Report disseminated: August 17, 2026 (14:32 EDT) 8 Company Update Coya Therapeutics, Inc. (COYA) • The author(s) of this report or their family members have no financial interest in the Issuer’s securities. • The author(s) of this report or their family members are not aware of any conflicts of interest that could have an influence on the content or publication of this report. • The author(s) of this report or their family members do not hold a sufficient quantity of the Issuer’s securities in their personal portfolios for the purpose of significant influence on stock prices in the event of their sale. • The reporting structure and remuneration of the author(s) do not create a conflict of interest. • The Company and its affiliated persons or related parties do not hold 1% or more of the total issued share capital of the Issuer. • The Company and its affiliated persons or related parties do not act as corporate brokers for the Issuer. • The Issuer does not hold a significant volume of shares of participation in the Company. • The Company may act as a market maker in relation to the Issuer’s shares. A detailed list of financial instruments is outlined on the Kazakhstan Stock Exchange website and is available via this link: https://kase.kz/ru/membership/SEVEN/ European Union Information and analytical services, along with materials, are provided by Freedom Finance Europe Ltd (hereinafter referred to as “FFE”) as part of the specified services and are not offered as an independent activity. FFE reserves the right to refuse service to individuals who do not meet the client criteria or are subject to bans or restrictions on such services under European Union law. Additional restrictions may also be enforced based on the FFE’s internal procedures and controls. FFE provides financial services in the European Union in accordance with license CIF 275/15 for all types of activities required by FFE as granted by the Cyprus Securities and Exchange Commission (CySEC) on May 20, 2015. Disclaimer: Additional information is available upon request. Investing in securities and other financial instruments always involves the risk of capital loss. The client must personally acknowledge this, including by reading the Risk Disclosure Notice. Opinions and estimates represent our judgments as of the date hereof and are subject to change without notice. Fees, charges and other expenses may reduce the financial performance of your investment. Past performance is not a reliable indicator of future results, and the value of investments may go up or down, potentially resulting in losses. There is no guarantee of future returns. This material is not intended to be an offer or solicitation to buy or sell any financial instrument. The opinions and recommendations provided herein do not consider any individual circumstances, goals or needs of the client and do not constitute an investment advisory service. Recipients of this report must make their own independent decisions in relation to any securities or financial instruments referred to herein. It is important to seek professional financial advice before making any investments, as this may lead to a strategic, well-informed approach that minimizes risks and maximizes long-term financial growth. We strongly recommend conducting thorough research and consulting with an independent financial advisor before making any investment decisions. The information has been obtained from sources that FFE believes to be reliable; its affiliates and/or subsidiaries do not guarantee completeness or accuracy of such information, save for disclosures related to FFE and/or its affiliates/agents and analyst's interactions with the issuer being the subject of research. All prices provided are indicative closing prices for the relevant securities, unless explicitly stated otherwise. FFE may trade the financial instruments referenced in this material as a counterparty or liquidity provider. However, all recommendations and information provided in this research report are independent and unaffected by FFE’s trading positions. We take all necessary measures to prevent conflicts of interest and uphold the objectivity of the information provided. Uzbekistan This report has been prepared by analysts of FREEDOM or an affiliate of Freedom Finance Foreign Enterprise Limited Liability Partnership (hereinafter referred to as the "FFFE"). Each analyst confirms that opinions and conclusions presented in this report regarding to securities or issuers reflect their personal point of view only. All recommendations and opinions presented in this report are current as of the publication date and have been prepared with maximum effort to ensure accuracy, completeness, and reliability. This report has been prepared independently of the FFFE, and all opinions and recommendations expressed herein are based on information available at the time of its preparation. Despite the measures taken to ensure the accuracy, completeness and reliability of the information provided, neither the analysts, FFFE, nor its directors or employees can guarantee absolute accuracy, completeness or reliability of the information. This report has been prepared taking into account the limitations and risks, which are inherent to the analysis of securities and financial markets and shall not be considered as an accurate prediction of future market conditions. FFFE, its employees, analysts, directors, and associated parties shall not be responsible for any losses or consequences resulting from the use of the information provided in this report for making investment decisions. The information contained in this report does not constitute an offer or recommendation to buy, sell, or otherwise dispose of securities. This report does not represent an assessment of the value of a business, its assets or its securities and can not be considered as a basis for making investment decisions. Past performance of securities or markets is not a guarantee of future performance. The selection of securities for investment, as well as the potential consequences is solely the risk of investor. Production completed: August 17, 2026 (14:32 EDT) Report disseminated: August 17, 2026 (14:32 EDT) 9 Company Update Coya Therapeutics, Inc. (COYA) FFFE, its employees, analysts and directors act in strict compliance with applicable legal requirements and standards of professional activity in the securities market. All materials in this report do not guarantee profit or constitute specific investment advice. The selection of securities for investment and its consequences are solely the risk of investor, who shall make decisions carefully, taking into account all risks associated with investments in the securities market. United Arab Emirates This Report is distributed in and from the Abu Dhabi Global Market ("ADGM") by Freedom Broker Global Markets Ltd ("FBGM"), a company incorporated in the ADGM (registration No. 25613) and authorised and regulated by the Financial Services Regulatory Authority of the ADGM (the "FSRA") under Financial Services Permission No. 250006. FBGM and Freedom Broker are affiliates, each being an indirect subsidiary of Freedom Holding Corp. (NASDAQ: FRHC). For the purposes of distribution in or from the ADGM, references in the disclosures contained in this Report to FREEDOM, the Firm or the Company include FBGM and its Associates (as defined in the FSRA Glossary Rulebook) only where the context relates to such ADGM distribution. This Report was prepared solely by Freedom Finance Global PLC and the analysts named herein. FBGM is a separate legal entity, did not participate in the preparation, review or independent verification of this Report, is not the author of the research contained herein and makes no representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein. To the fullest extent permitted by applicable law, FBGM accepts no liability for any loss or other consequence arising from the use of this Report; nothing in this Report excludes or restricts any duty or liability which FBGM may have under the ADGM Founding Law, the Financial Services and Markets Regulations 2015 or the rules of the FSRA. When distributing in or from the ADGM, this Report is directed only at Persons who meet the criteria of Professional Clients or Market Counterparties as defined in the FSRA Conduct of Business Rulebook. It is not directed at any other Person, and no other Person should act upon it; in particular, it must not be relied upon by or distributed to Retail Clients. For the purposes of distribution in or from the ADGM, this section prevails over any other statement in this Report regarding the persons to whom this Report is addressed or the categories of recipients who may receive or rely on it. By accepting this Report, the recipient represents that it is a Professional Client or a Market Counterparty and agrees not to distribute this Report to any other Person. This Report has not been reviewed, verified or approved by the FSRA or any other regulatory authority, and the FSRA accepts no responsibility for its contents. This Report is provided for information purposes only and does not constitute legal or tax advice, personal investment advice, a personal recommendation or an offer, solicitation or invitation to buy or sell any securities or other financial instruments. Trading in financial instruments involves a high degree of risk, including the risk of losing the entire invested capital; the value of investments and any income from them may fall as well as rise, and past performance is not a reliable indicator of future results. Recipients should make their own assessment of the merits and risks of any transaction and, where appropriate, obtain independent professional advice. Recipients in the ADGM should direct any queries regarding this Report to FBGM. Outside the ADGM, this Report is not directed at any person in the United Arab Emirates. FBGM is not licensed by the UAE Capital Market Authority (the "CMA") or by the Central Bank of the UAE. This Report has not been approved by, filed with or registered with the CMA, the Central Bank of the UAE or any other authority in the UAE outside the ADGM, does not constitute a promotion, offering or distribution of securities or financial products in the UAE outside the ADGM and must not be relied upon by any person in the UAE other than in circumstances permitted by applicable UAE law. The distribution of this Report in other jurisdictions, including elsewhere in the Middle East and North Africa, may be restricted by law. This Report is not directed at, and is not intended for distribution to or use by any person in any jurisdiction where such distribution or use would be contrary to applicable law or regulation or would subject FBGM or any of its affiliates to any registration or licensing requirement. Persons into whose possession this Report comes are required to inform themselves about, and to observe, any such restrictions.

Disclosures for Lake Street Capital Markets, Coya Therapeutics, August 11, 2026:

Lake Street Capital Markets, or its affiliates, intends to seek or expects to receive compensation for investment banking services from the subject issuer in the next three months. In the past 12 months, the subject company was a client of Lake Street and received investment banking services. In the past 12 months, Lake Street received investment banking compensation from the subject company. The authoring analysts who are responsible for the preparation of this investment research are eligible for compensation based on the total revenue and general profitability of Lake Street Capital Markets, which includes investment banking revenue. However, such authoring analyst will not receive compensation that is directly based on or linked to specific investment banking transactions. ANALYST CERTIFICATION – REGULATION AC Each authoring analyst of Lake Street Capital Markets whose name appears on the front page of this investment research hereby certifies that (1) the recommendations and opinions expressed in this investment research accurately reflect the authoring analyst’s personal, independent, and objective views about any and all of the subject investments or issuers discussed herein; and (2) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analysts. OTHER DISCLOSURES This investment research is intended for informational purposes only and does not constitute an offer or solicitation to buy or sell securities referenced herein in any jurisdiction where such would be prohibited. Although the information and statements of fact contained in this investment research have been obtained from sources we believe to be reliable, including statistical services and issuer statements & reports, its accuracy and completeness cannot be guaranteed. The securities discussed and any recommendations made herein may not be suitable for all investors depending on their specific financial position or investment objectives. This investment research and any opinions, recommendations, and estimates contained here represent Lake Street Capital Markets’ judgment as of the date of this report and are subject to change without notice. Lake Street Capital Markets may effect transactions as a principal or agent in the securities mentioned herein. Additional information available on request. Member FINRA / SIPC. This report may not be reproduced, distributed, or published without the prior consent of Lake Street Capital Markets, LLC. All rights reserved.

( Companies Mentioned: COYA:NASDAQ, )

Ultragenyx Delivers First Gene Therapy FDA Approval for GSDIa

Tue, 25 Aug 2026 00:00:00 PST

Source: Streetwise Reports 08/25/2026

Ultragenyx earns FDA approval for GENGLYCOS, its first gene therapy for GSDIa in patients aged 8 and older. Phase 3 data showed reduced cornstarch needs, with analyst price targets rising and a September UX111 decision ahead.

Ultragenyx Pharmaceutical Inc. (RARE:NASDAQ) achieved a major regulatory milestone when the FDA granted accelerated approval to GENGLYCOS, the company's first gene therapy and its fifth overall FDA approval. The therapy targets adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa).

Why the Approval Matters for Patients and Investors

GSDIa is an ultra-rare genetic metabolic disorder caused by an enzyme deficiency that prevents the liver from releasing glucose into the bloodstream, leading to life-threatening hypoglycemia. An estimated 1,500 to 2,500 patients live with the condition in the United States and 6,000 to 8,000 worldwide. Traditional management has relied on constant raw cornstarch intake to maintain blood sugar, a regimen that demands perfect adherence yet still carries risks of severe episodes.

It's the first FDA-approved treatment designed to target the underlying cause of GSDIa, a rare disorder affecting 1,500 to 2,500 patients in the U.S. This shift from symptom management to addressing the root genetic issue represents a fundamental change in how the disease can be treated.

Company Position and Manufacturing Advantage

Ultragenyx Pharmaceutical Inc. (RARE:NASDAQ) is a California-based biopharma firm focused exclusively on serious rare and ultra-rare genetic diseases. The newly approved therapy will be manufactured at the company's dedicated Gene Therapy Manufacturing Facility in Bedford, Massachusetts, and administered through specialized treatment centers across the country.

Key Investor Takeaways

The FDA approved GENGLYCOS for patients 8 and older with GSDIa based on Phase 3 data showing a statistically significant reduction in cornstarch requirements.
GENGLYCOS becomes the first approved therapy to address the genetic root cause rather than daily symptom management for this ultra-rare disease.
Ultragenyx received a Priority Review Voucher and must deliver two years of additional safety and efficacy data from 50 treated patients and 20 control patients.
Commercial launch is expected within 30 to 60 days at a $2.7 million wholesale acquisition cost.
Four of six recent analyst notes raised price targets following the approval, with the highest target now at $103.
Upcoming catalysts include a potential September FDA decision on UX111 for Sanfilippo syndrome type A and Phase 3 data for GTX-102 in Angelman syndrome.

Phase 3 Data and Post-Approval Commitments

The accelerated approval rests on results from the 48-week randomized double-blind placebo-controlled Phase 3 GlucoGene study involving 46 participants aged eight and older. Patients received either DTX401 at a dose of 1.0 x 10^13 GC/kg or placebo. The treated group showed a statistically significant reduction in cornstarch needs compared with placebo (p<0.001). Forty-four participants were included in the modified intention-to-treat analysis at week 48.

As a condition of accelerated approval, Ultragenyx is required to generate two years of additional safety and efficacy data through an expanded GSDIa Disease Monitoring Program. The company will provide two years of additional safety and efficacy data from 50 treated patients and 20 control patients through an expanded GSDIa Disease Monitoring Program, with the program following patients for a total of 10 years. The program will track both prior trial participants and new commercial patients for a total of 10 years while evaluating real-world cornstarch burden reduction and fasting tolerance.

Broader Sector Funding Trends

Biopharma funding declined 20 percent from 2024 to 2025, according to IQVIA analysis, yet 2025 remained the third-strongest year of the past decade. Global medicine usage is projected to approach four trillion defined daily doses by 2030, driven largely by innovative therapies in oncology, immunology, diabetes, and obesity. Companies are being encouraged to reduce the complexity and cost of advanced therapies while aligning trial designs more closely with real-world use from the outset.

Analyst Reactions and Valuation Context

Analyst coverage turned notably more constructive after the approval announcement. H.C. Wainwright reiterated a Buy rating with a $50 target, noting expected commercial availability within 30 to 60 days.

Recent updates tracked by Marketbeat include:

Canaccord Genuity raised its target from $81 to $83 while keeping a Buy rating.
Citigroup increased its target from $45 to $58 with a Buy rating.
Wells Fargo lifted its target from $45 to $46 while maintaining Overweight.
Cantor Fitzgerald raised its target from $96 to $103 with a Buy rating.

Two firms lowered targets in the same period, with Guggenheim moving from $43 to $35 and Wedbush adjusting from $27 to $26.

Upcoming Catalysts and Pipeline

Ultragenyx's August investor presentation highlights several near-term milestones. The FDA has assigned a September 19, 2026, PDUFA action date for UX111 in Sanfilippo syndrome type A. Phase 3 data for GTX-102 in Angelman syndrome could also arrive as early as September. For UX701 in Wilson disease, Stage 1 dose-finding data from cohorts 1-4 are anticipated by year-end 2026.

The company now has five approved medicines: Crysvita, Dojolvi, Mepsevii, Evkeeza, and GENGLYCOS.

Share Structure and Ownership¹

Ultragenyx holds a market capitalization of $2.59 billion with 98.59 million shares outstanding. The 52-week trading range spans $18.29 to $39.89. Institutions hold 58.75 percent of shares, strategic investors own 19.75 percent, and management plus insiders control 3.95 percent. [OWNERSHIP_CHART-6835]

Common Questions from Investors

Q: What is glycogen storage disease type Ia (GSDIa)?
A: GSDIa is a rare inherited metabolic disorder in which the body cannot properly release glucose from stored glycogen, leading to potentially dangerous episodes of low blood sugar.

Q: What is an accelerated FDA approval?
A: Accelerated approval is an FDA pathway that allows certain drugs for serious conditions to reach patients sooner based on evidence that they may provide meaningful clinical benefit, with additional studies required after approval.

Q: What is a Priority Review Voucher?
A: A Priority Review Voucher is an FDA incentive awarded to eligible companies for certain treatments, including some therapies for rare pediatric diseases. It can be used to receive priority review for another eligible product or sold or transferred to another company.

Q: Why is cornstarch used to treat GSDIa?
A: Cornstarch provides a source of glucose that can be absorbed gradually and helps people with GSDIa maintain blood sugar levels between meals and during periods of fasting.

Q: What is an AAV gene therapy?
A: An AAV gene therapy uses an adeno-associated virus, or AAV, as a delivery vehicle to transport genetic material into cells. AAV vectors are widely studied for delivering genes in treatments for inherited diseases.

Investors should weigh the commercial launch timeline, real-world data requirements, and broader rare-disease market dynamics when evaluating the stock.

Important Disclosures:

Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: RARE:NASDAQ, )

The Life Sciences Report

Rocket Doctor AI Delivers 3625 U.S. Patient Visits in July and August

Why the Visit Growth Matters Now

Company Advantage in Virtual Care Delivery

Key Assets and Next Catalysts

Broader Telehealth Sector Timing

Analyst Views and Valuation Context1

Share Structure and Near-Term Events2

Key Investor Takeaways

Common Questions from Investors

US Patient Visits Reach 93% of Prior Quarter's Total in Two Months

Virtual Care Moves Deeper Into U.S. Healthcare

Analysts Point to U.S. Expansion and Patient Growth

U.S. Expansion, Physician Capacity, and Value-Based Care

Ownership & Share Information2

FAQs

BioLargo Subsidiary Secures Spartan Medical Deal for ViaCLYR Government Sales

Why the Spartan Medical Agreement Matters Now

Company Advantage Through Clyrasept Technology

Key Assets and Next Catalysts

Broader Sector Timing and Market Growth

Analyst Views and Valuation Context

Share Structure and Near-Term Events2

Key Investor Takeaways

Common Questions from Investors

Sernova-Seraxis Merger to Create BetaNova with US$10M for T1D Islet Trial

Why the BetaNova Merger Matters for Investors Now

Combined Technology Platform Creates Differentiated Position

Key Development Milestones Backed by Financing

Orphan Drug Designation Adds Strategic Optionality

Diabetes Market Growth Provides Broad Tailwinds

Analyst Reaction and Valuation Context

Key Investor Takeaways

Ownership and Share Structure1

Common Questions from Investors

Biotechs Combine to Target Type 1 Diabetes Treatment

Sernova Wins Orphan Drug Designation for Cell Pouch Approach

Wainwright Keeps Buy, Trims Target on Merger Math

The Catalyst: Diabetes Drug Market Heading Toward US$283 Billion

Ownership and Share Structure1

Common Investor Questions

Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone

Why Healthcare?

Fundamental Share Price Catalysts

Grey Matters Versus Competitors

Ownership and Share Structure

Technical Analysis

Investor Risks

Investment Thesis Summary

Conclusion

Cleantech Firm Expands Breakthrough Wound Solution to Veterans

Clyra's ViaCLYR Added to Defense Logistics Agency Catalog

BioLargo Advances Its Businesses Toward Commercial Scale

Expert: Portfolio Covers Multiple Cleantech Markets

The Catalyst: A Growing Wound Care Market Lifts Demand

Ownership and Share Structure2

Common Investor Questions

Telehealth Platform Delivers 196% U.S. Visit Growth in Q2

Why the Q2 Results Matter for Investors

Platform Advantages and Payer Footprint

Key Growth Assets and Near-Term Catalysts

Telehealth Sector Timing

Analyst Views and Valuation Context

Share Structure and Liquidity2

Key Investor Takeaways

Common Questions from Investors

Rakovina Therapeutics Shifts 72% of Budget to AI Cancer Programs

Why the Budget Shift Matters for Investors Now

Company Focuses on AI-Validated DNA Damage Response Therapies

Key Programs and Next Catalysts

Broader Sector Timing and AI in Biotech

Key Investor Takeaways

Share Structure and Valuation Context1

Common Questions from Investors

Digital Health Platform Sees US Patient Visits Surge 196% and Quarterly YoY Revenue Jumps 43%

Telehealth Sector Continues Expanding

Analysts Maintain Bullish Outlook

What Could Drive Rocket Doctor's Next Stage of Growth

Ownership & Share Information2

Frequently Asked Questions

Analyst Views and Valuation Context¹

Share Structure and Near-Term Events²

Ownership & Share Information²

Share Structure and Near-Term Events²

Ownership and Share Structure¹

Ownership and Share Structure¹

Ownership and Share Structure²

Share Structure and Liquidity²

Share Structure and Valuation Context¹

Ownership & Share Information²

Ownership and Share Structure¹

Share Structure and Near-Term Events¹

Ownership & Share Information¹

Share Structure and Near-Term Events²

Share Structure and Ownership¹